WO2022113019A1 - A membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and the method of obtaining it - Google Patents
A membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and the method of obtaining it Download PDFInfo
- Publication number
- WO2022113019A1 WO2022113019A1 PCT/IB2021/061016 IB2021061016W WO2022113019A1 WO 2022113019 A1 WO2022113019 A1 WO 2022113019A1 IB 2021061016 W IB2021061016 W IB 2021061016W WO 2022113019 A1 WO2022113019 A1 WO 2022113019A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- membrane
- transition temperature
- base
- admixture
- hollow fiber
- Prior art date
Links
- 239000012528 membrane Substances 0.000 title claims abstract description 205
- 238000000034 method Methods 0.000 title claims abstract description 90
- 230000002429 anti-coagulating effect Effects 0.000 title claims abstract description 24
- 230000003110 anti-inflammatory effect Effects 0.000 title claims abstract description 23
- 239000011368 organic material Substances 0.000 title claims abstract description 16
- 239000000463 material Substances 0.000 claims abstract description 168
- 239000012510 hollow fiber Substances 0.000 claims abstract description 54
- 230000007704 transition Effects 0.000 claims abstract description 54
- 229920003023 plastic Polymers 0.000 claims abstract description 53
- 239000004033 plastic Substances 0.000 claims abstract description 53
- KXNPVXPOPUZYGB-XYVMCAHJSA-N argatroban Chemical compound OC(=O)[C@H]1C[C@H](C)CCN1C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C1=CC=CC2=C1NC[C@H](C)C2 KXNPVXPOPUZYGB-XYVMCAHJSA-N 0.000 claims abstract description 44
- 229960003856 argatroban Drugs 0.000 claims abstract description 44
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 41
- 229960002897 heparin Drugs 0.000 claims abstract description 41
- 229920000669 heparin Polymers 0.000 claims abstract description 41
- 230000008569 process Effects 0.000 claims abstract description 40
- 102000009027 Albumins Human genes 0.000 claims abstract description 38
- 108010088751 Albumins Proteins 0.000 claims abstract description 38
- 229940050528 albumin Drugs 0.000 claims abstract description 37
- OIRCOABEOLEUMC-GEJPAHFPSA-N bivalirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)CNC(=O)CNC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 OIRCOABEOLEUMC-GEJPAHFPSA-N 0.000 claims abstract description 35
- 229960001500 bivalirudin Drugs 0.000 claims abstract description 35
- 108010055460 bivalirudin Proteins 0.000 claims abstract description 35
- KANJSNBRCNMZMV-ABRZTLGGSA-N fondaparinux Chemical compound O[C@@H]1[C@@H](NS(O)(=O)=O)[C@@H](OC)O[C@H](COS(O)(=O)=O)[C@H]1O[C@H]1[C@H](OS(O)(=O)=O)[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O[C@@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O4)NS(O)(=O)=O)[C@H](O3)C(O)=O)O)[C@@H](COS(O)(=O)=O)O2)NS(O)(=O)=O)[C@H](C(O)=O)O1 KANJSNBRCNMZMV-ABRZTLGGSA-N 0.000 claims abstract description 34
- 229960001318 fondaparinux Drugs 0.000 claims abstract description 34
- 238000010276 construction Methods 0.000 claims abstract description 25
- UHKAJLSKXBADFT-UHFFFAOYSA-N 1,3-indandione Chemical compound C1=CC=C2C(=O)CC(=O)C2=C1 UHKAJLSKXBADFT-UHFFFAOYSA-N 0.000 claims abstract description 20
- UESSERYYFWCTBU-UHFFFAOYSA-N 4-(n-phenylanilino)benzaldehyde Chemical compound C1=CC(C=O)=CC=C1N(C=1C=CC=CC=1)C1=CC=CC=C1 UESSERYYFWCTBU-UHFFFAOYSA-N 0.000 claims abstract description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 90
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 90
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 60
- 239000011888 foil Substances 0.000 claims description 56
- 230000015572 biosynthetic process Effects 0.000 claims description 53
- 239000000203 mixture Substances 0.000 claims description 47
- -1 poly(tetrafluoroethylene) Polymers 0.000 claims description 37
- 229920001343 polytetrafluoroethylene Polymers 0.000 claims description 34
- 239000008240 homogeneous mixture Substances 0.000 claims description 30
- 238000004519 manufacturing process Methods 0.000 claims description 30
- 239000011541 reaction mixture Substances 0.000 claims description 30
- 239000002033 PVDF binder Substances 0.000 claims description 26
- 229920002981 polyvinylidene fluoride Polymers 0.000 claims description 26
- 239000007864 aqueous solution Substances 0.000 claims description 24
- 238000001816 cooling Methods 0.000 claims description 24
- 230000003247 decreasing effect Effects 0.000 claims description 21
- 230000001965 increasing effect Effects 0.000 claims description 21
- 239000004743 Polypropylene Substances 0.000 claims description 20
- 239000004744 fabric Substances 0.000 claims description 20
- 229920001155 polypropylene Polymers 0.000 claims description 20
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 18
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 claims description 18
- 239000008187 granular material Substances 0.000 claims description 16
- 229920000139 polyethylene terephthalate Polymers 0.000 claims description 16
- 239000005020 polyethylene terephthalate Substances 0.000 claims description 16
- 238000001953 recrystallisation Methods 0.000 claims description 16
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 238000009835 boiling Methods 0.000 claims description 15
- 238000004440 column chromatography Methods 0.000 claims description 15
- 238000010992 reflux Methods 0.000 claims description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicon dioxide Inorganic materials O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 12
- 229930040373 Paraformaldehyde Natural products 0.000 claims description 12
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 12
- 239000011521 glass Substances 0.000 claims description 12
- 229920002492 poly(sulfone) Polymers 0.000 claims description 12
- 229920006324 polyoxymethylene Polymers 0.000 claims description 12
- 239000004814 polyurethane Substances 0.000 claims description 12
- 239000004753 textile Substances 0.000 claims description 11
- 239000004417 polycarbonate Substances 0.000 claims description 10
- 229920000515 polycarbonate Polymers 0.000 claims description 10
- 229910052786 argon Inorganic materials 0.000 claims description 9
- 229920001577 copolymer Polymers 0.000 claims description 9
- HCDGVLDPFQMKDK-UHFFFAOYSA-N hexafluoropropylene Chemical group FC(F)=C(F)C(F)(F)F HCDGVLDPFQMKDK-UHFFFAOYSA-N 0.000 claims description 9
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 claims description 9
- 239000012298 atmosphere Substances 0.000 claims description 8
- 229920002313 fluoropolymer Polymers 0.000 claims description 8
- 239000004811 fluoropolymer Substances 0.000 claims description 8
- 229910052724 xenon Inorganic materials 0.000 claims description 8
- FHNFHKCVQCLJFQ-UHFFFAOYSA-N xenon atom Chemical compound [Xe] FHNFHKCVQCLJFQ-UHFFFAOYSA-N 0.000 claims description 8
- 239000011261 inert gas Substances 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 6
- 239000002798 polar solvent Substances 0.000 claims description 5
- 239000004809 Teflon Substances 0.000 claims description 4
- 229920006362 Teflon® Polymers 0.000 claims description 4
- 239000000919 ceramic Substances 0.000 claims description 4
- 229920005573 silicon-containing polymer Polymers 0.000 claims description 4
- 229910001220 stainless steel Inorganic materials 0.000 claims description 4
- 239000010935 stainless steel Substances 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 2
- 238000003490 calendering Methods 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 239000013543 active substance Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 abstract description 50
- 239000008280 blood Substances 0.000 abstract description 50
- 238000006213 oxygenation reaction Methods 0.000 abstract description 41
- 239000011148 porous material Substances 0.000 description 55
- 239000007789 gas Substances 0.000 description 32
- 239000000243 solution Substances 0.000 description 32
- 230000003204 osmotic effect Effects 0.000 description 26
- 208000007536 Thrombosis Diseases 0.000 description 25
- 238000013270 controlled release Methods 0.000 description 21
- 229910052799 carbon Inorganic materials 0.000 description 20
- 239000012300 argon atmosphere Substances 0.000 description 14
- BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-Difluoroethene Chemical compound FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- 239000003146 anticoagulant agent Substances 0.000 description 12
- 229940127219 anticoagulant drug Drugs 0.000 description 11
- 239000012299 nitrogen atmosphere Substances 0.000 description 8
- 239000003868 thrombin inhibitor Substances 0.000 description 7
- 229940123900 Direct thrombin inhibitor Drugs 0.000 description 6
- 108090000190 Thrombin Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 229960004072 thrombin Drugs 0.000 description 6
- 210000001772 blood platelet Anatomy 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 229920002635 polyurethane Polymers 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 4
- 108010073385 Fibrin Proteins 0.000 description 4
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 229950003499 fibrin Drugs 0.000 description 4
- 239000003112 inhibitor Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 206010053567 Coagulopathies Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000032770 biofilm formation Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 210000003527 eukaryotic cell Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000014508 negative regulation of coagulation Effects 0.000 description 3
- 229920000098 polyolefin Polymers 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010014522 Embolism venous Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 102000004882 Lipase Human genes 0.000 description 2
- 108090001060 Lipase Proteins 0.000 description 2
- 239000004367 Lipase Substances 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 238000004220 aggregation Methods 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 239000004019 antithrombin Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000000678 effect on lipid Effects 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 229940083124 ganglion-blocking antiadrenergic secondary and tertiary amines Drugs 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 235000019421 lipase Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000004043 venous thromboembolism Diseases 0.000 description 2
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 229940122388 Thrombin inhibitor Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940127090 anticoagulant agent Drugs 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000002598 diffusion tensor imaging Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical class C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000010687 lubricating oil Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000001706 oxygenating effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229920000447 polyanionic polymer Polymers 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 239000013047 polymeric layer Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 239000010453 quartz Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012959 renal replacement therapy Methods 0.000 description 1
- 238000004062 sedimentation Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/0005—Use of materials characterised by their function or physical properties
- A61L33/0011—Anticoagulant, e.g. heparin, platelet aggregation inhibitor, fibrinolytic agent, other than enzymes, attached to the substrate
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/06—Flat membranes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L33/00—Antithrombogenic treatment of surgical articles, e.g. sutures, catheters, prostheses, or of articles for the manipulation or conditioning of blood; Materials for such treatment
- A61L33/06—Use of macromolecular materials
- A61L33/064—Use of macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0002—Organic membrane manufacture
- B01D67/0009—Organic membrane manufacture by phase separation, sol-gel transition, evaporation or solvent quenching
- B01D67/0011—Casting solutions therefor
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0002—Organic membrane manufacture
- B01D67/002—Organic membrane manufacture from melts
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D67/00—Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
- B01D67/0002—Organic membrane manufacture
- B01D67/0023—Organic membrane manufacture by inducing porosity into non porous precursor membranes
- B01D67/0025—Organic membrane manufacture by inducing porosity into non porous precursor membranes by mechanical treatment, e.g. pore-stretching
- B01D67/0027—Organic membrane manufacture by inducing porosity into non porous precursor membranes by mechanical treatment, e.g. pore-stretching by stretching
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/02—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor characterised by their properties
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D69/00—Semi-permeable membranes for separation processes or apparatus characterised by their form, structure or properties; Manufacturing processes specially adapted therefor
- B01D69/08—Hollow fibre membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/26—Polyalkenes
- B01D71/261—Polyethylene
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/26—Polyalkenes
- B01D71/262—Polypropylene
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/30—Polyalkenyl halides
- B01D71/32—Polyalkenyl halides containing fluorine atoms
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/30—Polyalkenyl halides
- B01D71/32—Polyalkenyl halides containing fluorine atoms
- B01D71/34—Polyvinylidene fluoride
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/30—Polyalkenyl halides
- B01D71/32—Polyalkenyl halides containing fluorine atoms
- B01D71/36—Polytetrafluoroethene
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/48—Polyesters
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/50—Polycarbonates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/52—Polyethers
- B01D71/521—Aliphatic polyethers
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/54—Polyureas; Polyurethanes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/66—Polymers having sulfur in the main chain, with or without nitrogen, oxygen or carbon only
- B01D71/68—Polysulfones; Polyethersulfones
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/70—Polymers having silicon in the main chain, with or without sulfur, nitrogen, oxygen or carbon only
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2313/00—Details relating to membrane modules or apparatus
- B01D2313/68—Biocompatibility of parts of the module
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2323/00—Details relating to membrane preparation
- B01D2323/15—Use of additives
- B01D2323/218—Additive materials
- B01D2323/2182—Organic additives
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2325/00—Details relating to properties of membranes
- B01D2325/04—Characteristic thickness
Definitions
- the object of the invention is a membrane made of an organic material with pore forming, anti-inflammatory and anticoagulant properties, intended in particular for the construction of medical devices and the method of obtaining it.
- Materials with pore-forming properties are used to make selective membranes, that is, membranes that only allow particles of a certain size to pass through. Such materials are used, among other things, to make membranes for use in the manufacture of everyday objects such as: tents, jackets, filters, but also osmotic membranes for medical applications: in filters for renal replacement therapy and in oxygenators for blood oxygenation.
- membranes including porous membranes used in devices having direct contact with body fluids, made of various materials.
- PL225257 patent description presents a membrane system for local immobilization of eukaryotic cells, having a support and at least one bilayer formed of successively one polyelectrolyte layer comprising polysaccharide hydrogels, especially sodium alginate containing in its structure incorporated fullerenol and protein A, characterized in that the first layer is applied directly to the group of isolated cells then placed on a support made of the same material in terms of composition, and, a second polymeric layer of aliphatic secondary and tertiary amines - containing ethyl or methyl groups with incorporated fullerenol.
- a single layer is applied directly to a group of isolated eukaryotic cells, and it allows eukaryotic cells to be isolated from the external environment, particularly microorganisms, while not restricting nutrient transport across the membrane, allowing for directed growth.
- PL212620 patent description presents a specially modified polyolefin membrane (PP, PE) and a method of modifying microporous polyolefin membranes intended for the isolation of Gram (+) bacteria, consisting in that a solution of polycation, selected from the group consisting of aliphatic amino acids, especially protein amino acids, preferably polar and dissolved in NaCl solution, is then introduced into the structure of a polyolefin membrane of high porosity in a known way, preferably by soaking, and then the solution of polyanion, selected from the group consisting of polymeric secondary and tertiary amines, especially methylamine and ethylamine, preferably containing 100% methyl or ethyl groups, dissolved in the solution of NaCl.
- a solution of polycation selected from the group consisting of aliphatic amino acids, especially protein amino acids, preferably polar and dissolved in NaCl solution
- polyanion selected from the group consisting of polymeric secondary and tertiary
- PL165872 patent description presents a method for producing a multilayer porous membrane of poly(tetrafluoroethylene) containing at least two layers having pores of different average diameters, which includes the steps of: filling the extruder barrel with at least two different types of fine poly(tetrafluoroethylene) powders, with a liquid lubricant mixed with each.
- EP0409496 patent description presents a process for preparing microporous membranes containing at least a partially crystalline aromatic polymer containing ether or thioether and ketone bonds in the chain.
- the process allows membranes to be made from certain aromatic polymers with high melting points, such as PEDK.
- polypropylene (PP) and polyurethane (PU) have mainly been used as pore forming materials in medical applications.
- polyurethane was used as a porous material for the construction of membranes
- polypropylene was used for the construction of elements for separation of membrane layers (spacers).
- spacers the high efficiency of such membranes in terms of gas exchange, they have limitations mainly related to the initiation of inflammatory reaction from the low bioinertness of these materials. This affected the formation of progressively growing thrombi on the membrane surface.
- albumins - blood proteins produced in the liver and responsible for maintaining oncotic pressure in blood vessels, transport of substances poorly soluble in plasma (fatty acids, some hormones, calcium ions) and buffering blood.
- the anti-inflammatory effects of albumins include inhibition of leukotriene production by neutrophils and thrombocytes and decreased sensitivity of neutrophils to inflammatory cytokines.
- their anticoagulant effect is through activation of antithrombin III and inhibition of thrombocyte aggregation.
- argatroban a synthetic analogue of hirudin, which is a small- molecule direct thrombin inhibitor (DTI) used for anticoagulant therapy in patients with heparin-induced thrombocytopenia type II who require parenteral anticoagulant therapy.
- DTI direct thrombin inhibitor
- the first mechanism of DTI activity involves blocking the active site of thrombin, whereas the second involves inhibition of the fibrin binding site, where the substrate is recognized and spatially correctly oriented.
- the activity of these inhibitors is direct and does not depend on the presence of antithrombin. Unlike indirect DTI inhibitors, they can inhibit fibrin-bound thrombin.
- Bivalirudin is also known - an anticoagulant from a group of direct specific thrombin inhibitors (DTI).
- DTIs block the active site responsible for the main thrombin activity and/or the external site where the substrate is recognized and spatially correctly oriented.
- the activity of these inhibitors is direct and does not depend on the presence of antithrombin.
- they can inhibit fibrin -bound thrombin, which prevents thrombin from splitting fibrinogen to fibrin monomers, activating factors XIII, V, VIII, and stimulating thrombocytes to aggregate.
- a compound with an anticoagulant effect is also fondaparinux - an organic chemical compound, an oligosaccharide.
- Fondaparinux is used as an anticoagulant to prevent the formation of thrombi and is used as standard in patients undergoing surgery and immobilized due to disease, in venous thromboembolism, acute coronary syndromes.
- Heparin an organic chemical compound, a polysaccharide composed primarily of N-sulfate and O-sulfate of glycosaminoglycan made up of D-glucosamine and L-iduronic acid radical linked into an unbranched chain, also exhibits anticoagulant activity.
- Heparin is a natural agent that, by inhibiting the transition of prothrombin to thrombin, causes a potent blood anticoagulant effect and, due to its effect on lipids through lipase activation, is also used as an anticoagulant used for anticoagulant coatings. When released in a controlled manner, it can also inhibit thrombocyte aggregation and adhesion (sticking to surfaces) to blood vessel walls. Heparin is trapped by the vessel walls and increases their negative charge, making it difficult for thrombocytes to adhere and preventing the formation of wall clots. Heparin is used as an anticoagulant drug to prevent thrombus formation, standard treatment for patients undergoing surgery and immobilized due to a disease, in venous thromboembolism, acute coronary syndromes.
- its essence is a membrane characterized in that it is in the form of a flat foil with a thickness from 0.2 to 200 pm, preferably 30 pm, or a tube with an outer diameter from 30 to 600 pm, preferably 100 pm, and, is made of an organic material having pore-forming, anti-inflammatory and anticoagulant properties comprising:
- - base in the form of a fluoropolymer, preferably poly(tetrafluoroethylene) (PTFE, Teflon) or polyvinylidene fluoride (PVDF) or a copolymer of tetrafluoroethylene and hexafluoropropylene (FEP), and
- PTFE poly(tetrafluoroethylene)
- PVDF polyvinylidene fluoride
- FEP hexafluoropropylene
- the essence of it is a membrane characterized in that it is in the form of a flat foil with a thickness from 0.2 to 200 pm, preferably 30 pm, or a tube with an outer diameter from 30 to 600 pm, preferably 100 pm, and, is made of an organic material having pore-forming, anti-inflammatory and anticoagulant properties comprising: - base in the form of polypropylene (PP) or polyurethane (PU) or polyethylene terephthalate (PET) or polycarbonate (PC) or polyoxymethylene (POM) or polysulfone (PSU) or silicone or fluoropolymer, preferably poly(tetrafluoroethylene) (PTFE) or polyvinylidene fluoride (PVDF) or a copolymer of tetrafluoroethylene and hexafluoropropylene (FEP),
- PP polypropylene
- PU polyurethane
- PET polyethylene terephthalate
- PC polycarbonate
- POM polyoxymethylene
- the essence of the invention also comprises a method for obtaining a membrane made of an organic material with pore-forming, anti-inflammatory and anticoagulant properties, in the first variation, characterized in that a material in the form of a fluoropolymer, preferably poly(tetrafluoroethylene) (PTFE, Teflon) or poly vinylidene fluoride (PVDF) or a copolymer of tetrafluoroethylene and hexafluoropropylene (FEP) is extruded on a linear head in the form of a string, preferably with an outer diameter of 2 to 10 mm, or on a cross head in the form of a tube, preferably with an outer diameter of 2 to 10 mm, or on a flat head in the form of a foil preferably with a thickness of 0.1 to 3 mm, then the process of immobilization of active admixture in the form of albumin or argatroban or bivalirudin or fondaparinux or heparin into
- the material obtained in the first step in the form of a string is brought to a temperature within ⁇ 30°C from the plastic transition temperature, preferably exactly to the plastic transition temperature, after which it is stretched - by known methods - on calenders, preferably in two directions, so as to obtain a membrane in the form of a flat foil with a thickness between 0.2 and 200 pm, preferably 30 pm, or
- the essence of the invention also comprises a method for obtaining a membrane from an organic material with pore-forming, anti-inflammatory and anticoagulant properties, in a second variation, characterized in that in the first step a material for the membrane is produced in such a way that a polar solvent and an acid selected from the following ones are introduced into a reactor made of a non-reactive material in an inert (neutral) gas atmosphere: sulfuric acid VI, hydrochloric acid or acetic acid, in proportions from 2 ⁇ 0.002 to 7 ⁇ 0.002, preferably 5 ⁇ 0.002, and then per 50mL of a mixture thus formed, 4-(diphenylamino)benzaldehyde in the amount from 0.2g to 0.7g and 1,3-indandione in the amount of O.Olg to 0.08g are added and stirred until a homogeneous mixture is obtained in no less than 1 minute, after which the suspension is washed with inert gas for at least 5 minutes, preferably not more than 60 minutes,
- the resulting mixture is cooled to 20 to 35°C and subjected to column chromatography in a S1O2 bed and in the mobile phase of the mixture of hexane and methylene chloride, in the amounts of hexane from 0.5 to 2 times the volume of the reaction mixture, and methylene chloride from 0.5 to 2 times the volume of the reaction mixture.
- the product is then vacuum-dried for at least 20 hours, preferably 24 hours to constant weight, after which it is recrystallized from chloroform.
- the product after recrystallization from chloroform is placed in a homogenizer and the base is introduced as: polypropylene (PP) or polyurethane (PU) or polyethylene terephthalate (PET) or polycarbonate (PC) or polyoxymethylene (POM) or polysulfone (PSU) or silicone or fluoropolymer, preferably poly(tetrafluoroethylene) (PTFE) or polyvinylidene fluoride (PVDF) or a copolymer of tetrafluoroethylene and hexafluoropropylene (FEP), in the ratio of base/recrystallizate from 50 ⁇ 2 to 5000 ⁇ 2, preferably 100 ⁇ 2, and then mixed to a homogeneous mixture and dried for at least 20 hours at 80-110°C, after which the material is extruded on a linear head is extruded on a linear head in the form of a string, preferably with an outer diameter of 2 to 10 mm, or
- the material obtained in the first step in the form of a string is brought to a temperature within ⁇ 30°C from the plastic transition temperature, preferably exactly to the plastic transition temperature, after which it is stretched - by known methods - on calenders, preferably in two directions, so as to form a membrane in the form of a flat foil with a thickness between 0.2 and 200pm, preferably 30pm, or
- tubular material obtained in the first step is brought to a temperature within ⁇ 30°C from the plastic transition temperature, preferably exactly to the plastic transition temperature, and is then stretched - by known methods - on calenders, preferably in two directions, so as to obtain a membrane in the form of a tube with an outer diameter between 30 and 600pm, preferably 100pm, or
- a porous membrane is formed, since during the stretching process pores with a size of 1 nm to 150 pm are produced, the membrane contains pores of which 40 to 60% are open pores (not filled) and the remaining pores are closed pores, i.e. they are filled with the active admixture.
- the active admixture is gradually released and thus consumed, and the total amount of active admixture decreases and the number of open pores increases, resulting in a larger gas exchange surface area, i.e., better oxygenation.
- New pores are also formed that take over the gas exchange function from open pores that may have been blocked by progressively forming thrombi or biofilm formation on the membrane surface.
- hollow fiber tubes are obtained, which due to the porous structure of the wall can serve as cylindrical gas exchange membranes.
- the tubes obtained in variant b) are cut into pieces of an appropriate length and then knitted on textile machines to form a membrane, most preferably with a distance of about 35 pm between the individual hollow fiber tubes in the knitted fabric and in this form they can preferably be used as membranes for oxygenating blood in oxygenators.
- the first step of the method according to the invention in the second variation is carried out in a glass or ceramic or stainless steel reactor.
- the first step of the method according to the invention in the second variation is carried out in a reactor in the form of a round-bottomed three-necked flask, due to its good functional properties.
- argon or nitrogen or xenon is used as the inert gas.
- anhydrous ethanol is used as the polar solvent.
- the base material is added in the form of a crushed material or aggregate or most preferably granulate.
- a cyclic decrease and increase of the stress is applied, which increases the efficiency of the immobilization of the active admixture in the pores of the material.
- a membrane is obtained having pores oriented in the direction or directions of stretching. Their characteristic feature is the absence of sharp edges and cracks around the pores.
- Such membrane materials characterized by pores with irregular morphology prevent low molecular weight materials, including organic ones, from depositing in the vicinity of possible pore fractures.
- the membrane thanks to its smooth surfaces and pore orientation along the flow path, reduces the risk of thrombosis due to the absence of steric obstacles that could be centers of thrombosis (no thrombi formation on the surface of the material occurs).
- These types of membranes are relatively fragile, with little resistance to external forces.
- such membranes can be used in their manufactured form due to the absence of external forces that can break the continuity of the material.
- the membrane film membrane is exposed to external forces, especially outdoor membranes (such as membranes for construction of tents)
- the membranes obtained by the methods according to the invention are characterized by full controllability of the size of the pores formed as well as their arrangement along the axis of flow of gases and body fluids, which results in higher gas exchange efficiency.
- the analyses show that such membranes have better selectivity performance than membranes with rough edges at the pore boundaries.
- the solution according to the invention makes it possible to obtain membranes with a very wide range of pore sizes from nano/micro scale (application especially for oxygenation, gas exchange) to macro pore size of even tenths of a millimeter (application as waterproof, breathable materials).
- the membrane is characterized by low flow resistance, i.e., it enables to maintain proper, i.e., unobstructed flow despite low pressure - which is a result of the directional pore arrangement created by the directional stretching process on the calenders and the orientation of the macromolecules that results from such stretching. In the absence of this orientation of the pore system, turbulence would occur to interfere with the flow, resulting in an increase in flow resistance and consequently an increase in pressure.
- a decrease in gas flow pressure on one side of the membrane results in an increase in oxygen saturation while maintaining flow parameters, which results in better oxygenation of blood flowing on the other side of the membrane due to the maintenance of laminar flow continuity.
- An additional advantage is that the material used does not release chemicals toxic to cells and does not itself cause pathogenic reactions on cells.
- a membrane constructed from the materials described above protects against biofilm formation (no bacterial plaque forms on it), due to the internal structure of the material, i.e. the arrangement of macromolecules and pores in the material, which is not a protagonist of bacterial plaque development and adhesion.
- the chemical structure of macromolecules of materials for construction of membranes obtained by the method according to the invention affects their good pore-forming, anti inflammatory and anticoagulant properties and at the same time ensures their biocompatibility and bioinertness (full neutrality).
- these materials are used to manufacture membranes for oxygenators, the risk of inducing inflammation in cells is reduced, and thus the process of coagulation on the membrane slows down.
- the method according to the invention makes it possible to obtain membranes made of materials with a pore size in the nano range so that a single molecule of oxygen and carbon dioxide is able to penetrate the pores, and at the same time so that the pores are smaller than the macromolecular packets of which body fluids are composed, which in effect makes it possible to effectively oxygenate the blood without the risk of blood molecules penetrating the pores.
- the method of pore formation in the process of directional stretching causes the pores to be oriented along the longitudinal axis of the hollow fiber tube or foil which ensures laminarity of the flow (the flow is not turbulent).
- the disc was positioned so that possible sedimentation of the analyte from the solvent would not falsify the result by gravitational settling on the disc. Positioning of the disc ensured that only the mass of the absorbed analyte was measured. Based on the observed changes in the frequency of disc vibrations (decrease of vibrations), the presence of an active admixture in the solvent was found to be deposited on the electrode. This indicates that when the membrane was immersed in the solvent, the active admixture was released from the membrane into the solvent. The experiment was repeated ten times on the same sample and the measurement results were similar each time (within the measurement error). The constancy of the changes over time indicates a controlled process of releasing the active admixture from the membrane.
- an immobilized active admixture allows its concentration on the part contact surface to remain constant throughout the application of the materials (planned product life). The possibility of excessive leaching of the active admixture is minimized, and because of the diffusion-controlled release of the active admixture, its contact concentration on the product surface is constant.
- the active admixture as noted above has potent blood anticoagulant activity and due to its effect on lipids through lipase activation it is also used as an anticoagulant agent used for anticoagulant coatings.
- the active admixture is embedded both in the pores of the material and in microcracks formed as equilibrium defects during the material formation step. This significantly improves the surface continuity of the material structure and thus prevents organic material from depositing in pores and microcracks and significantly reduces coagulation.
- a method for preparing a membrane made of an organic material with pore-forming, anti-inflammatory and anticoagulant properties according to the invention will be further explained by means of the following examples.
- PTFE granules are introduced into a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for PTFE and hollow fiber tubes with an outer diameter of 2 mm are extruded on a cross head, and in the next step the process of immobilization of albumin into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PTFE-albumin ratio of 1200 ⁇ 1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of albumin to a temperature of 180°C, i.e.
- the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a hollow fiber tube is brought to a temperature of 175°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a hollow fiber tube with an outer diameter of 600pm.
- a membrane with albumin introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of albumin, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
- the hollow fiber tubes thus obtained can be spun on textile machines into knitted fabrics so that in the knitted fabric the distance between individual hollow fiber tubes is 35 pm and in this form they can be used as membranes for blood oxygenation in oxygenators.
- PTFE granules are introduced into a twin-screw ten-zone extruder with counter-rotating screws arrangement and geometry specified for PTFE and a foil of thickness 3 mm is extruded on a flat head and in the next step the process of immobilization of albumin into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PTFE/albumin ratio of 80 ⁇ 1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of albumin to 300°C, i.e. below the plastic transition temperature, it is stretched on calenders, by cyclically decreasing and increasing the tension, so as to obtain an elongation of 5 times, which results in the formation of micropores in which albumin is immobilized.
- the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a flat foil is brought to a temperature of 295°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a 200 pm thick flat foil.
- a membrane with albumin introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of albumin, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
- PVDF aggregate is introduced into a twin-screw ten-zone extruder with counter-rotating screws arrangement and geometry specified for PVDF and a string with an outer diameter of 10 mm is extruded on a linear head and in the next step the process of immobilization of argatroban into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PVDF/argatroban ratio of 150 ⁇ 1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of argatroban to 185°C, i.e.
- the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a foil is brought to a temperature of 180°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a 0,2pm thick foil.
- a membrane with argatroban introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of argatroban, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
- membranes can be used as gas-exchanging surfaces in flat membrane oxygenators or as osmotic membranes.
- Milled FEP is introduced into a twin-screw ten-zone extruder with counter-rotating screws arrangement and geometry specified for FEP and hollow fiber tubes with an outer diameter of 10 mm are extruded on a cross head and in the next step the process of immobilization of argatroban into the steric structure of the material obtained in such a way that its content in the material in the FEP/argatroban ratio of 150 ⁇ 1 is carried out in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of argatroban to a temperature of 245°C, i.e. below the plastic transition temperature, it is stretched on calenders by cyclically decreasing and increasing the tension so as to obtain an elongation of 10 times, which results in the formation of micropores in which argatroban is immobilized.
- the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a hollow fiber tube is brought to a temperature of 240°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a hollow fiber tube with an outer diameter of 30mih.
- a membrane with argatroban introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of argatroban, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
- the hollow fiber tubes thus obtained can be spun on textile machines into knitted fabrics so that in the knitted fabric the distance between individual hollow fiber tubes is 35 pm and in this form they can be used as membranes for blood oxygenation in oxygenators.
- membranes can be used as gas-exchanging surfaces in flat membrane oxygenators or as osmotic membranes.
- PVDF granulate is introduced into a twin-screw ten-zone extruder with counter-rotating screws arrangement and geometry specified for PVDF and a string with an outer diameter of 2 mm is extruded on a linear head and in the next step the process of immobilization of bivalirudin into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material with the PVDF/bivalirudin ratio of 150 ⁇ 1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of bivalirudin to 185°C, i.e. below the plastic transition temperature, it is linearly stretched on calenders, so as to obtain an elongation of 20 times, which results in the formation of micropores in which bivalirudin is immobilized.
- the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a string is brought to a temperature of 180°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of 0.2pm thick foil.
- a membrane with bivalirudin introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of bivalirudin, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
- membranes can be used as gas-exchanging surfaces in flat membrane oxygenators or as osmotic membranes.
- the method according to the invention makes it possible to obtain membranes made of materials with anti-inflammatory and anticoagulant properties, especially for the construction of medical equipment, in particular for components which are in direct contact with blood.
- Such membranes may, among other things, be used in oxygenators for blood oxygenation and as other gas- selective membranes.
- PTFE granules are introduced into a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for PTFE and hollow fiber tubes with an outer diameter of 2 mm are extruded on a cross head and in the next step the process of immobilization of fondaparinux into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PTFE/fondaparinux ratio of 1200 ⁇ 1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of fondaparinux to a temperature of 180°C, i.e. below the plastic transition temperature, it is stretched on calenders, by cyclically decreasing and increasing the tension so as to obtain an elongation of 10 times, which results in the formation of micropores in which fondaparinux is immobilized.
- the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a hollow fiber tube is brought to a temperature of 175°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a hollow fiber tube with an outer diameter of 600p
- a membrane with fondaparinux introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of fondaparinux, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
- the tubes thus obtained can be spun on textile machines into knitted fabrics so that in the knitted fabric the distance between individual hollow fiber tubes is 35 pm and in this form they can be used as membranes for blood oxygenation in oxygenators.
- PTFE granules are introduced into a twin-screw ten-zone extruder with counter-rotating screws arrangement and geometry specified for PTFE and a foil of thickness 3 mm is extruded on a flat head and in the next step the process of immobilization of heparin into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PTFE/heparin ratio of 80 ⁇ 1, in such a way in that after initial cooling in a bath containing a supersaturated aqueous solution of heparin to 300°C, i.e. below the plastic transition temperature, it is stretched on calenders, by cyclically decreasing and increasing the tension, so as to obtain an elongation of 5 times, which results in the formation of micropores in which heparin is immobilized.
- the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a flat foil is brought to a temperature of 295°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a 200 pm thick flat foil.
- a membrane with heparin introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of heparin, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
- membranes can be used as gas-exchanging surfaces in flat membrane oxygenators or as osmotic membranes.
- the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and sulfuric acid (VI) in proportions of 5 ⁇ 0.002 is introduced into a dried round bottom three-neck glass flask in an argon atmosphere and 0.3 g of 4- (diphenylamino)benzaldehyde and 0.06 g of 1,3-indandione are added.
- the mixture is homogenized by stirring for 5 minutes and purged with argon for 30 minutes. It is then heated up to boiling under a reflux condenser in an argon atmosphere and stirred intensely at 400 rpm for 24 hours.
- the solution is cooled down to 30°C and subjected to column chromatography in a S1O2 bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 1 times the volume of the reaction mixture, and of methylene chloride equal to 0.5 times the volume of the reaction mixture.
- the product is then vacuum-dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform.
- the product after recrystallization from chloroform (recry stallizate) is placed in a homogenizer and 300 g of polycarbonate (PC) granulate are added.
- PC polycarbonate
- the solution is mixed until a homogeneous mixture is obtained and dried for 24 hours at 90°C. Then - using a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for PC - hollow fiber tubes with an outer diameter of 2 mm are extruded on a cross head, and in the next step the process of immobilization of albumin into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PC/albumin ratio of 150 ⁇ 1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of albumin to a temperature of 180°C, i.e. below the plastic transition temperature, it is stretched on calenders, by cyclically decreasing and increasing the tension so as to obtain an elongation of 8 times, which results in the formation of micropores in which albumin is immobilized.
- the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a hollow fiber tube is brought to a temperature of 175°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a flat hollow fiber tube with an outer diameter of 30pm
- a membrane with albumin introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of albumin, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
- the tubes thus obtained can be spun on textile machines into knitted fabrics so that in the knitted fabric the distance between individual hollow fiber tubes is 35 pm and in this form they can be used as membranes for blood oxygenation in oxygenators.
- the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and hydrochloric acid in proportions of 5 ⁇ 0.002 is introduced into a dried stainless steel reactor in a xenon atmosphere and 0.5 g of 4- (diphenylamino)benzaldehyde and 0.02 g of 1,3-indandione are added.
- the mixture is homogenized by stirring for 1 minute and purged with xenon for 10 minutes. It is then heated up to boiling under a reflux condenser in a xenon atmosphere and stirred intensely at 350 rpm for 20 hours.
- the solution is cooled down to 35°C and subjected to column chromatography in a SiC bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 2 times the volume of the reaction mixture, and of methylene chloride equal to 1 times the volume of the reaction mixture.
- the product is then vacuum-dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform.
- the product after recrystallization from chloroform (recry stallizate) is placed in a homogenizer and 25g polyurethane (PU) aggregate are added.
- the solution is mixed until a homogeneous mixture is obtained and dried for 20 hours at 105°C.
- the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a hollow fiber tube is brought to a temperature of 175°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a hollow fiber tube with an outer diameter of 600pm.
- a membrane with albumin introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of albumin, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
- the tubes thus obtained can be spun on textile machines into knitted fabrics so that in the knitted fabric the distance between individual hollow fiber tubes is 30 pm and in this form they can be used as membranes for blood oxygenation in oxygenators.
- the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and acetic acid in proportions of 5 ⁇ 0.002 is introduced into a dried round bottom three-neck glass flask in an argon atmosphere and 0.7 g of 4- (diphenylamino)benzaldehyde and 0.08 g of 1,3-indandione are added.
- the mixture is homogenized by stirring for 3 minutes and purged with argon for 45 minutes. It is then heated up to boiling under a reflux condenser in an argon atmosphere and stirred intensely at 450 rpm for 24 hours.
- the solution is cooled down to 30°C and subjected to column chromatography in a S1O2 bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 1 times the volume of the reaction mixture, and of methylene chloride equal to 0.5 times the volume of the reaction mixture.
- the product is then vacuum-dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform.
- the product after recrystallization from chloroform (recry stallizate) is placed in a homogenizer and 350 g of milled polypropylene (PP) are added.
- PP milled polypropylene
- the solution is mixed until a homogeneous mixture is obtained and dried for 24 hours at 110°C. Then - using a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for polypropylene - a hollow fiber tube with an outer diameter of 10 mm is extruded from the material on a cross head, and in the next step the process of immobilization of argatroban into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PP/argatroban ratio of 80 ⁇ 1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of argatroban to a temperature of 150°C, i.e. below the plastic transition temperature, it is stretched on calenders, by cyclically decreasing and increasing the tension so as to obtain an elongation of 20 times, which results in the formation of micropores in which argatroban is immobilized.
- the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a hollow fiber tube is brought to a temperature of 145°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a hollow fiber tube with an outer diameter of 100 pm.
- a membrane with argatroban introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of argatroban, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
- the tubes thus obtained can be spun on textile machines into knitted fabrics so that in the knitted fabric the distance between individual hollow fiber tubes is 35 pm and in this form they can be used as membranes for blood oxygenation in oxygenators.
- the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and acetic acid in proportions of 5 ⁇ 0.002 is introduced into a dried ceramic reactor in an argon atmosphere and 0.7 g of 4-(diphenylamino)benzaldehyde and 0.08 g of 1,3-indandione are added.
- the mixture is homogenized by stirring for 2 minutes and purged with argon for 45 minutes. It is then heated up to boiling under a reflux condenser in an argon atmosphere and stirred intensely at 450 rpm for 24 hours.
- the solution is cooled down to 30°C and subjected to column chromatography in a S1O2 bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 1 times the volume of the reaction mixture, and of methylene chloride equal to 0.5 times the volume of the reaction mixture.
- the product is then vacuum-dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform.
- the product after recrystallization from chloroform (recrystallizate) is placed in a homogenizer and 350 g of poly(ethylene terephthalate) (PET) granulate are added.
- PET poly(ethylene terephthalate)
- the solution is mixed until a homogeneous mixture is obtained and dried for 24 hours at 110°C. Then - using a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for PET - a 1 mm thick foil is extruded from the material on a flat head, and in the next step the process of immobilization of argatroban into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PET/argatroban ratio of 700 ⁇ 1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of argatroban to a temperature of 230°C, i.e.
- the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a foil is brought to a temperature of 225°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a 1 Opm thick flat foil.
- a membrane with argatroban introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of argatroban, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
- the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and sulfuric acid (VI) in proportions of 6 ⁇ 0.002 is introduced into a dried round bottom three-neck glass flask in a nitrogen atmosphere and 0.7 g of 4-(diphenylamino)benzaldehyde and 0.08 g of 1,3-indandione are added.
- the mixture is homogenized by stirring for 1 minute and purged with nitrogen for 35 minutes. It is then heated up to boiling under a reflux condenser in a nitrogen atmosphere and stirred intensely at 600 rpm for 30 hours.
- the solution is cooled down to 25°C and subjected to column chromatography in a S1O2 bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 0.5 times the volume of the reaction mixture, and of methylene chloride equal to 0.5 times the volume of the reaction mixture.
- the product is then vacuum-dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform.
- the product after recrystallization from chloroform (recry stallizate) is placed in a homogenizer and 71 g of poly(tetrafluoroethylene) (PTFE) granulate are added.
- PTFE poly(tetrafluoroethylene)
- the solution is mixed until a homogeneous mixture is obtained and dried for 24 hours at 100°C. Then - using a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for poly(tetrafluoroethylene) - a 0.5 mm thick foil is extruded from the material on a flat head, and in the next step the process of immobilization of argatroban into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PTFE/argatroban ratio of 450 ⁇ 1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of argatroban to a temperature of 300°C, i.e.
- the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a foil is brought to a temperature of 295°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a 5 pm thick flat foil.
- a membrane with argatroban introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of argatroban, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
- the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and hydrochloric acid in proportions of 3 ⁇ 0.002 is introduced into a dried round bottom three-neck glass flask in a nitrogen atmosphere and 0.7 g of 4-(diphenylamino)benzaldehyde and 0.08 g of 1,3-indandione are added.
- the mixture is homogenized by stirring for 2 minutes and purged with nitrogen for 60 minutes. It is then heated up to boiling under a reflux condenser in a nitrogen atmosphere and stirred intensely at 500 rpm for 24 hours.
- the solution is cooled down to 25°C and subjected to column chromatography in a S1O2 bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 2 times the volume of the reaction mixture, and of methylene chloride equal to 2 times the volume of the reaction mixture.
- the product is then vacuum-dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform.
- the product after recrystallization from chloroform (recry stallizate) is placed in a homogenizer and 140 g of poly oxy methylene (POM) granulate are added.
- POM poly oxy methylene
- the solution is mixed until a homogeneous mixture is obtained and dried for 20 hours at 110°C. Then - using a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for POM - an 8 mm thick string is extruded from the material on a linear head, and in the next step the process of immobilization of bivalirudin into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the POM/bivalirudin ratio of 100 ⁇ 1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of bivalirudin to a temperature of 180°C, i.e.
- the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a string is brought to a temperature of 175°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a 35 pm thick flat foil.
- a membrane with bivalirudin introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of bivalirudin, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
- the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and hydrochloric acid in proportions of 3 ⁇ 0.002 is introduced into a dried round bottom three-neck glass flask in a nitrogen atmosphere and 0.7 g of 4-(diphenylamino)benzaldehyde and 0.08 g of 1,3-indandione are added.
- the mixture is homogenized by stirring for 2 minutes and purged with nitrogen for 60 minutes. It is then heated up to boiling under a reflux condenser in nitrogen atmosphere and stirred intensely at 900 rpm for 20 hours.
- the solution is cooled down to 25°C and subjected to column chromatography in a S1O2 bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 2 times the volume of the reaction mixture, and of methylene chloride equal to 2 times the volume of the reaction mixture.
- the product is then vacuum-dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform.
- the product after recrystallization from chloroform (recry stallizate) is placed in a homogenizer and 310 g of polysulfone (PSU) granulate are added.
- PSU polysulfone
- the solution is mixed until a homogeneous mixture is obtained and dried for 30 hours at 90°C. Then - using a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for polysulfone - a 3 mm thick foil is extruded from the material on a flat head, and in the next step the process of immobilization of bivalirudin into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PSU/bivalirudin ratio of 1200 ⁇ 1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of bivalirudin to a temperature of 190°C, i.e.
- the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a foil is brought to a temperature of 185°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a 200pm thick flat foil.
- a membrane with bivalimdin introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of bivalimdin, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
- the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and sulfuric acid (VI) in proportions of 5 ⁇ 0.002 is introduced into a dried round bottom three-neck glass flask in an argon atmosphere and 0.3 g of 4-(diphenylamino)benzaldehyde and 0.06 g of 1,3-indandione are added.
- the mixture is homogenized by stirring for 4 minutes and purged with argon for 30 minutes. It is then heated up to boiling under a reflux condenser in an argon atmosphere and stirred intensely at 500 rpm for 24 hours.
- the solution is cooled down to 30°C and subjected to column chromatography in a S1O2 bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 0.5 times the volume of the reaction mixture, and of methylene chloride equal to 0.5 times the volume of the reaction mixture.
- the product is then vacuum-dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform.
- the product after recrystallization from chloroform (recry stallizate) is placed in a homogenizer and 150 g of polyvinylidene fluoride (PVDF) granulate are added.
- PVDF polyvinylidene fluoride
- the solution is mixed until a homogeneous mixture is obtained and dried for 24 hours at 90°C. Then - using a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for PVDF - a 2.5 mm thick foil is extruded from the material on a flat head, and in the next step the process of immobilization of bivalirudin into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PVDF/bivalirudin ratio of 150 ⁇ 1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of bivalirudin to a temperature of 185°C, i.e.
- the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a foil is brought to a temperature of 180°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a 1 p thick flat foil.
- a membrane with bivalirudin introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of bivalirudin, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
- the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and hydrochloric acid in proportions of 2 ⁇ 0.002 is introduced into a dried round-bottomed triple-necked glass flask in a nitrogen atmosphere and 0.5 g of 4- (diphenylamino)benzaldehyde and 0.02 g of 1,3-indandione are added.
- the mixture is homogenized by stirring for 1 minute and purged with nitrogen for 10 minutes. It is then heated up to boiling under a reflux condenser in a nitrogen atmosphere and stirred intensely at 400 rpm for 30 hours.
- the solution is cooled down to 25°C and subjected to column chromatography in a S1O2 bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 2 times the volume of the reaction mixture, and of methylene chloride equal to 2 times the volume of the reaction mixture.
- the product is then vacuum-dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform.
- the product after recrystallization from chloroform (recry stallizate) is placed in a homogenizer and 50 g of a copolymer of tetrafluoroethylene and hexafluoropropylene (FEP) granulate are added. The solution is mixed until a homogeneous mixture is obtained and dried for 30 hours at 95°C.
- FEP hexafluoropropylene
- the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a foil is brought to a temperature of 240°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a 30pm thick flat foil.
- a membrane with fondaparinux introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of fondaparinux, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
- the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and sulfuric acid (VI) in proportions of 5 ⁇ 0.002 is introduced into a dried round bottom three-neck glass flask in an argon atmosphere and 0.3 g of 4-(diphenylamino)benzaldehyde and 0.06 g of 1,3-indandione are added.
- the mixture is homogenized by stirring for 5 minutes and purged with argon for 30 minutes. It is then heated up to boiling under a reflux condenser in an argon atmosphere and stirred intensely at 400 rpm for 24 hours.
- the solution is cooled down to 30°C and subjected to column chromatography in a SiC bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 1 times the volume of the reaction mixture, and of methylene chloride equal to 0.5 times the volume of the reaction mixture.
- the product is then vacuum-dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform.
- the product after recrystallization from chloroform (recry stallizate) is placed in a homogenizer and 300 g of polycarbonate (PC) granulate are added.
- PC polycarbonate
- the solution is mixed until a homogeneous mixture is obtained and dried for 24 hours at 90°C. Then - using a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for PC - hollow fiber tubes with an outer diameter of 2 mm are extruded from the material on a cross head, and in the next step the process of immobilization of fondaparinux into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PC/fondaparinux ratio of 150 ⁇ 1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of fondaparinux to a temperature of 180°C, i.e.
- the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a hollow fiber tube is brought to a temperature of 175°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a flat hollow fiber tube with an outer diameter of 30pm.
- a membrane with fondaparinux introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of fondaparinux, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
- the tubes thus obtained can be spun on textile machines into knitted fabrics so that in the knitted fabric the distance between individual hollow fiber tubes is 35 pm and in this form they can be used as membranes for blood oxygenation in oxygenators.
- the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and hydrochloric acid in proportions of 5 ⁇ 0.002 is introduced into a dried stainless steel reactor in a xenon atmosphere and 0.5 g of 4- (diphenylamino)benzaldehyde and 0.02 g of 1,3-indandione are added.
- the mixture is homogenized by stirring for 1 minute and purged with xenon for 10 minutes. It is then heated up to boiling under a reflux condenser in a xenon atmosphere and stirred intensely at 350 rpm for 20 hours.
- the solution is cooled down to 35°C and subjected to column chromatography in a SiC bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 2 times the volume of the reaction mixture, and of methylene chloride equal to 1 times the volume of the reaction mixture.
- the product is then vacuum-dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform.
- the product after recrystallization from chloroform (recry stallizate) is placed in a homogenizer and 25g polyurethane (PU) aggregate are added.
- the solution is mixed until a homogeneous mixture is obtained and dried for 20 hours at 105°C.
- the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a hollow fiber tube is brought to a temperature of 175°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a hollow fiber tube with an outer diameter of 600pm.
- a membrane with heparin introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of heparin, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
- the tubes thus obtained can be spun on textile machines into knitted fabrics so that in the knitted fabric the distance between individual hollow fiber tubes is 30 pm and in this form they can be used as membranes for blood oxygenation in oxygenators.
- the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and acetic acid in proportions of 5 ⁇ 0.002 is introduced into a dried round-bottomed triple-necked glass flask in an argon atmosphere and 0.7 g of 4- (diphenylamino)benzaldehyde and 0.08 g of 1,3-indandione are added.
- the mixture is homogenized by stirring for 3 minutes and purged with argon for 45 minutes. It is then heated up to boiling under a reflux condenser in an argon atmosphere and stirred intensely at 450 rpm for 24 hours.
- the solution After obtaining a homogeneous mixture, the solution is cooled down to 30°C and subjected to column chromatography in a S1O2 bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 1 times the volume of the reaction mixture, and of methylene chloride equal to 0.5 times the volume of the reaction mixture. It is then vacuum-dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform. The product after recrystallization from chloroform (recry stallizate) is placed in a homogenizer and 350g of milled polypropylene (PP) are added.
- PP milled polypropylene
- the solution is mixed until a homogeneous mixture is obtained and dried for 24 hours at 110°C. Then - using a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for polypropylene - a hollow fiber tube with an outer diameter of 10 mm is extruded from the material on a cross head, and in the next step the process of immobilization of heparin into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PP/heparin ratio of 80 ⁇ 1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of heparin to a temperature of 150°C, i.e. below the plastic transition temperature, it is stretched on calenders, by cyclically decreasing and increasing the tension so as to obtain an elongation of 20 times, which results in the formation of micropores in which heparin is immobilized.
- the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a hollow fiber tube is brought to a temperature of 145°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a hollow fiber tube with an outer diameter of 100 pm.
- a membrane with heparin introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of heparin, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
- the tubes thus obtained can be spun on textile machines into knitted fabrics so that in the knitted fabric the distance between individual hollow fiber tubes is 35 pm and in this form they can be used as membranes for blood oxygenation in oxygenators.
- the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and acetic acid in proportions of 5 ⁇ 0.002 is introduced into a dried ceramic reactor in an argon atmosphere and 0.7 g of 4-(diphenylamino)benzaldehyde and 0.08 g of 1,3-indandione are added.
- the mixture is homogenized by stirring for 2 minutes and purged with argon for 45 minutes. It is then heated up to boiling under a reflux condenser in an argon atmosphere and stirred intensely at 450 rpm for 24 hours.
- the solution is cooled down to 30°C and subjected to column chromatography in a S1O2 bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 1 times the volume of the reaction mixture, and of methylene chloride equal to 0.5 times the volume of the reaction mixture. It is then vacuum- dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform. The product after recrystallization from chloroform (recrystallizate) is placed in a homogenizer and 350 g of poly(ethylene terephthalate) (PET) granulate are added.
- PET poly(ethylene terephthalate)
- the solution is mixed until a homogeneous mixture is obtained and dried for 24 hours at 110°C. Then - using a twin- screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for PET - a 1 mm thick foil is extruded from the material on a flat head, and in the next step the process of immobilization of heparin into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PET/heparin ratio of 700 ⁇ 1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of heparin to a temperature of 230°C, i.e.
- the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a foil is brought to a temperature of 225°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a 1 Opm thick flat foil.
- a membrane with heparin introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of heparin, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
- the method according to the invention makes it possible to obtain membranes made of materials with pore-forming, anti-inflammatory and anticoagulant properties, especially intended for the construction of medical equipment, in particular for construction of components which are in direct contact with blood.
- membranes may, among other things, be used in oxygenators for blood oxygenation and as other gas-selective membranes.
Landscapes
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Manufacturing & Machinery (AREA)
- General Health & Medical Sciences (AREA)
- Materials Engineering (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Materials For Medical Uses (AREA)
- External Artificial Organs (AREA)
Abstract
The object of the invention is a membrane made of an organic material with pore-forming, anti-inflammatory and anticoagulant properties, characterized in that it has the form of a flat film or a hollow fiber tube and is made of an organic material with pore-forming, anti-inflammatory and anticoagulant properties consisting of a base polymeric material and an active admixture in the form of albumin or argatroban or bivalirudin or fondaparinux or heparin, embedded in the micro structure of the base material in a base/active admixture ratio from 80÷1 to 1200÷1, and, in case of some types of base polymeric materials, also of 4-(diphenylamino)benzaldehyde admixture in the base/admixture ratio from 50÷1 to 5000÷1 and 1,3-indandione admixture in a base/admixture ratio from 50÷1 to 5000÷1. An object of the invention is also a method for obtaining a membrane from an organic material having pore-forming, anti-inflammatory and anticoagulant properties, characterized in that the base polymeric material is extruded on a linear head in the form of a string or on a cross head in the form of a hollow fiber tube or on a flat head in the form of a film, after which the process of immobilization of the active admixture in the form of albumin or argatroban or bivalirudin or fondaparinux or heparin to the steric structure of the material thus obtained in such a way to ensure its content in the material in the base/active admixture ratio from 80÷1 to 1200÷1 is carried out, then, the second, final step of producing the membrane is carried out in such a way that the material obtained at the first step is brought to a temperature within ±30°C from the plastic transition temperature, after which - by known methods - it is stretched on calenders. For some types of the base polymeric material, an admixture of 4-(diphenylamino)benzaldehyde and 1,3-indandione is introduced into the material in the initial stage of its preparation. The method according to the invention makes it possible to obtain membranes made of materials with pore-forming, anti-inflammatory and anticoagulant properties, especially intended for the construction of medical equipment, in particular for construction of components which are in direct contact with blood. Among other things, the solution may find application as an essential component of blood oxygenation devices or as other gas-selective membranes.
Description
A MEMBRANE MADE OF AN ORGANIC MATERIAL WITH PORE-FORMING, ANTI-INFLAMMATORY AND ANTICOAGULANT PROPERTIES AND THE
METHOD OF OBTAINING IT
The object of the invention is a membrane made of an organic material with pore forming, anti-inflammatory and anticoagulant properties, intended in particular for the construction of medical devices and the method of obtaining it.
Materials with pore-forming properties are used to make selective membranes, that is, membranes that only allow particles of a certain size to pass through. Such materials are used, among other things, to make membranes for use in the manufacture of everyday objects such as: tents, jackets, filters, but also osmotic membranes for medical applications: in filters for renal replacement therapy and in oxygenators for blood oxygenation.
The most common, high-tech - in non-medical applications - pore-forming material (used, for example, in the manufacture of jackets), from which membranes were made is poly (tetrafluoroethylene) .
However, in medical applications, i.e. for the construction of medical devices, from the current state of technology, there are known membranes, including porous membranes used in devices having direct contact with body fluids, made of various materials.
For example, PL225257 patent description presents a membrane system for local immobilization of eukaryotic cells, having a support and at least one bilayer formed of successively one polyelectrolyte layer comprising polysaccharide hydrogels, especially sodium alginate containing in its structure incorporated fullerenol and protein A, characterized in that the first layer is applied directly to the group of isolated cells then placed on a support made of the same material in terms of composition, and, a second polymeric layer of aliphatic secondary and tertiary amines - containing ethyl or methyl groups with incorporated fullerenol. In this system, a single layer is applied directly to a group of isolated eukaryotic cells, and it allows eukaryotic cells to be isolated from the external environment, particularly microorganisms, while not restricting nutrient transport across the membrane, allowing for directed growth.
PL212620 patent description presents a specially modified polyolefin membrane (PP, PE) and a method of modifying microporous polyolefin membranes intended for the isolation of Gram (+) bacteria, consisting in that a solution of polycation, selected from the group consisting of aliphatic amino acids, especially protein amino acids, preferably polar and dissolved in NaCl solution, is then introduced into the structure of a polyolefin membrane of high porosity in a known way, preferably by soaking, and then the solution of polyanion,
selected from the group consisting of polymeric secondary and tertiary amines, especially methylamine and ethylamine, preferably containing 100% methyl or ethyl groups, dissolved in the solution of NaCl.
PL165872 patent description presents a method for producing a multilayer porous membrane of poly(tetrafluoroethylene) containing at least two layers having pores of different average diameters, which includes the steps of: filling the extruder barrel with at least two different types of fine poly(tetrafluoroethylene) powders, with a liquid lubricant mixed with each.
EP0409496 patent description presents a process for preparing microporous membranes containing at least a partially crystalline aromatic polymer containing ether or thioether and ketone bonds in the chain. The process allows membranes to be made from certain aromatic polymers with high melting points, such as PEDK.
The type of materials from which the membranes known from the above solutions were made allows - for steric reasons - their use for blood oxygenation, however their significant biochemical limitations significantly limit this application. This is because these membranes did not contain additives to provide anticoagulant release, which was a significant disadvantage in such applications. Moreover, due to their structure, they are characterized by developed surface topography on the micrometer scale, which was the reason for their negative effects on living organisms. At the cellular level, these membranes cause steric damage to cell membranes, resulting in cell destabilization. Furthermore, membranes cannot inhibit thrombus formation and do not protect against bacterial biofilm formation.
So far, polypropylene (PP) and polyurethane (PU) have mainly been used as pore forming materials in medical applications. For example, in devices used in the process of oxygenation of blood, polyurethane was used as a porous material for the construction of membranes, and polypropylene was used for the construction of elements for separation of membrane layers (spacers). Despite the high efficiency of such membranes in terms of gas exchange, they have limitations mainly related to the initiation of inflammatory reaction from the low bioinertness of these materials. This affected the formation of progressively growing thrombi on the membrane surface. In this case, in order to maintain the effectiveness of blood oxygenation, it was necessary to increase the oxygen concentration, which induces oxidative stress and intensifies the clotting process, triggering an unfavorable cascade of rapidly successive adverse factors, because the oxygen concentration must be constantly increased to maintain the blood saturation level, and this intensifies oxidative stress and enhances clotting. After crossing a certain threshold, the amount of thrombi is already so high that the device is
no longer suitable for further operation (does not perform its function) and the entire oxygenator system must be replaced.
Consequently, there was a need to develop membranes made of materials not known so far, especially for medical applications, that would allow for a high level of anti-inflammatory and anticoagulant properties, while also ensuring their biocompatibility and bioinertness (neutrality) when in contact with patient’s blood. The reason for using the new material for the membrane in the oxygenator is the need to reduce the risk of inducing inflammation, thereby slowing down the clotting process on the membrane and extending the life of the device.
Various compounds with anticoagulant activity are known from the state of the art. Among others, we know albumins - blood proteins produced in the liver and responsible for maintaining oncotic pressure in blood vessels, transport of substances poorly soluble in plasma (fatty acids, some hormones, calcium ions) and buffering blood. The anti-inflammatory effects of albumins include inhibition of leukotriene production by neutrophils and thrombocytes and decreased sensitivity of neutrophils to inflammatory cytokines. On the other hand, their anticoagulant effect is through activation of antithrombin III and inhibition of thrombocyte aggregation. Also known is argatroban, a synthetic analogue of hirudin, which is a small- molecule direct thrombin inhibitor (DTI) used for anticoagulant therapy in patients with heparin-induced thrombocytopenia type II who require parenteral anticoagulant therapy. The first mechanism of DTI activity involves blocking the active site of thrombin, whereas the second involves inhibition of the fibrin binding site, where the substrate is recognized and spatially correctly oriented. The activity of these inhibitors is direct and does not depend on the presence of antithrombin. Unlike indirect DTI inhibitors, they can inhibit fibrin-bound thrombin. Bivalirudin is also known - an anticoagulant from a group of direct specific thrombin inhibitors (DTI). DTIs block the active site responsible for the main thrombin activity and/or the external site where the substrate is recognized and spatially correctly oriented. The activity of these inhibitors is direct and does not depend on the presence of antithrombin. Unlike indirect DTI inhibitors, they can inhibit fibrin -bound thrombin, which prevents thrombin from splitting fibrinogen to fibrin monomers, activating factors XIII, V, VIII, and stimulating thrombocytes to aggregate. A compound with an anticoagulant effect is also fondaparinux - an organic chemical compound, an oligosaccharide. It is a synthetic pentasaccharide with a sequence identical with the pentasaccharide hydrolysis products of fondaparinux, and contains an additional methyl group at the reducing end. It is a selective inhibitor of factor Xa. Fondaparinux is used as an anticoagulant to prevent the formation of thrombi and is used as standard in patients undergoing surgery and immobilized due to disease, in venous
thromboembolism, acute coronary syndromes. Heparin, an organic chemical compound, a polysaccharide composed primarily of N-sulfate and O-sulfate of glycosaminoglycan made up of D-glucosamine and L-iduronic acid radical linked into an unbranched chain, also exhibits anticoagulant activity. Heparin is a natural agent that, by inhibiting the transition of prothrombin to thrombin, causes a potent blood anticoagulant effect and, due to its effect on lipids through lipase activation, is also used as an anticoagulant used for anticoagulant coatings. When released in a controlled manner, it can also inhibit thrombocyte aggregation and adhesion (sticking to surfaces) to blood vessel walls. Heparin is trapped by the vessel walls and increases their negative charge, making it difficult for thrombocytes to adhere and preventing the formation of wall clots. Heparin is used as an anticoagulant drug to prevent thrombus formation, standard treatment for patients undergoing surgery and immobilized due to a disease, in venous thromboembolism, acute coronary syndromes.
So far, however, there are no known membranes made of materials with pore-forming, anti-inflammatory and anticoagulant properties, containing immobilized in their composition active admixtures of albumin, argatroban, bivalirudin, fondaparinux or heparin, semi- permeable to gases, intended especially for use in medical gas exchange systems, especially for blood oxygenation (oxygenators) and effective ways of obtaining such membranes, and their development has become the aim of the authors of the present invention.
In the first variation of the invention, its essence is a membrane characterized in that it is in the form of a flat foil with a thickness from 0.2 to 200 pm, preferably 30 pm, or a tube with an outer diameter from 30 to 600 pm, preferably 100 pm, and, is made of an organic material having pore-forming, anti-inflammatory and anticoagulant properties comprising:
- base in the form of a fluoropolymer, preferably poly(tetrafluoroethylene) (PTFE, Teflon) or polyvinylidene fluoride (PVDF) or a copolymer of tetrafluoroethylene and hexafluoropropylene (FEP), and
- active admixture in the form of albumin or argatroban or bivalirudin or fondaparinux or heparin, embedded in the micro structure of the base material, in the ratio of base/active admixture from 80÷1 to 1200÷1, preferably 150÷1.
In the second variation of the invention, the essence of it is a membrane characterized in that it is in the form of a flat foil with a thickness from 0.2 to 200 pm, preferably 30 pm, or a tube with an outer diameter from 30 to 600 pm, preferably 100 pm, and, is made of an organic material having pore-forming, anti-inflammatory and anticoagulant properties comprising:
- base in the form of polypropylene (PP) or polyurethane (PU) or polyethylene terephthalate (PET) or polycarbonate (PC) or polyoxymethylene (POM) or polysulfone (PSU) or silicone or fluoropolymer, preferably poly(tetrafluoroethylene) (PTFE) or polyvinylidene fluoride (PVDF) or a copolymer of tetrafluoroethylene and hexafluoropropylene (FEP),
- 4-(diphenylamino)benzaldehyde admixture with the base/admixture ratio from 50÷1 to 5000÷1, preferably 100÷1,
- admixture of 1,3-indandione with the base/admixture ratio from 50÷1 to 5000÷1, preferably 100÷1, and
- active admixture in the form of albumin or argatroban or bivalirudin or fondaparinux or heparin, embedded in the micro structure of the base material, in the proportion of base/active admixture from 80÷1 to 1200÷1, preferably 150÷1.
The essence of the invention also comprises a method for obtaining a membrane made of an organic material with pore-forming, anti-inflammatory and anticoagulant properties, in the first variation, characterized in that a material in the form of a fluoropolymer, preferably poly(tetrafluoroethylene) (PTFE, Teflon) or poly vinylidene fluoride (PVDF) or a copolymer of tetrafluoroethylene and hexafluoropropylene (FEP) is extruded on a linear head in the form of a string, preferably with an outer diameter of 2 to 10 mm, or on a cross head in the form of a tube, preferably with an outer diameter of 2 to 10 mm, or on a flat head in the form of a foil preferably with a thickness of 0.1 to 3 mm, then the process of immobilization of active admixture in the form of albumin or argatroban or bivalirudin or fondaparinux or heparin into the steric structure of the material thus obtained is carried out in a manner ensuring its content in the material with the base/active admixture ratio from 80÷1 to 1200÷1, preferably 150÷1, in such a way, that after initial cooling in a bath containing a supersaturated aqueous solution of the active admixture to a temperature within ±30°C from the plastic transition temperature, preferably below the plastic transition temperature, it is stretched on calenders (by known methods of forming fibers or foils) to obtain an elongation of 5-20 times, preferably 10 times, which results in the formation of micropores in which the active admixture immobilizes, whereby in the variant with an extruded string, the elongation process is carried out linearly - maintaining the string form, or in two directions - forming a flat foil from the string. The second and final step of membrane production is then carried out, which is performed in three ways depending on the form of the material obtained in step one, that is, either:
- according to variant a), wherein the material obtained in the first step in the form of a string is brought to a temperature within ±30°C from the plastic transition temperature, preferably exactly to the plastic transition temperature, after which it is stretched - by known methods - on
calenders, preferably in two directions, so as to obtain a membrane in the form of a flat foil with a thickness between 0.2 and 200 pm, preferably 30 pm, or
- according to variant b), wherein the material in the form of a hollow fiber tube obtained in the first step is brought to a temperature within ±30°C from the plastic transition temperature, preferably exactly to the plastic transition temperature, and is then stretched - by known methods on calenders - preferably in two directions, to obtain a membrane in the form of a tube with an outer diameter between 30 and 600 pm, preferably 100 pm, or
- according to variant c), wherein the material obtained in the first step in the form of a foil is brought to a temperature within ±30°C from the plastic transition temperature, preferably exactly to the plastic transition temperature, after which it is stretched - by known methods - on calenders, preferably in two directions, so as to obtain a membrane in the form of a flat foil with a thickness between 0.2 and 200 pm, preferably 30 pm.
The essence of the invention also comprises a method for obtaining a membrane from an organic material with pore-forming, anti-inflammatory and anticoagulant properties, in a second variation, characterized in that in the first step a material for the membrane is produced in such a way that a polar solvent and an acid selected from the following ones are introduced into a reactor made of a non-reactive material in an inert (neutral) gas atmosphere: sulfuric acid VI, hydrochloric acid or acetic acid, in proportions from 2 ÷ 0.002 to 7 ÷ 0.002, preferably 5 ÷ 0.002, and then per 50mL of a mixture thus formed, 4-(diphenylamino)benzaldehyde in the amount from 0.2g to 0.7g and 1,3-indandione in the amount of O.Olg to 0.08g are added and stirred until a homogeneous mixture is obtained in no less than 1 minute, after which the suspension is washed with inert gas for at least 5 minutes, preferably not more than 60 minutes, heated to boiling under a reflux condenser in an inert gas atmosphere and stirred intensely at 100-1000 rpm, preferably 350-450 rpm for at least 18 hours, preferably not more than 30 hours. After the mixing process, the resulting mixture is cooled to 20 to 35°C and subjected to column chromatography in a S1O2 bed and in the mobile phase of the mixture of hexane and methylene chloride, in the amounts of hexane from 0.5 to 2 times the volume of the reaction mixture, and methylene chloride from 0.5 to 2 times the volume of the reaction mixture. The product is then vacuum-dried for at least 20 hours, preferably 24 hours to constant weight, after which it is recrystallized from chloroform. The product after recrystallization from chloroform (recry stallizate) is placed in a homogenizer and the base is introduced as: polypropylene (PP) or polyurethane (PU) or polyethylene terephthalate (PET) or polycarbonate (PC) or polyoxymethylene (POM) or polysulfone (PSU) or silicone or fluoropolymer, preferably poly(tetrafluoroethylene) (PTFE) or polyvinylidene fluoride (PVDF) or a copolymer of
tetrafluoroethylene and hexafluoropropylene (FEP), in the ratio of base/recrystallizate from 50÷2 to 5000÷2, preferably 100÷2, and then mixed to a homogeneous mixture and dried for at least 20 hours at 80-110°C, after which the material is extruded on a linear head is extruded on a linear head in the form of a string, preferably with an outer diameter of 2 to 10 mm, or on a cross head in the form of a tube, preferably with an outer diameter of 2 to 10 mm, or on a flat head in the form of a foil preferably with a thickness of 0.1 to 3 mm, and in the next step the process of immobilization of active admixture in the form of albumin or argatroban or bivalirudin or fondaparinux or heparin into the steric structure of the material thus obtained is carried out in a manner ensuring its content in the material with the base/active admixture ratio from 80÷1 to 1200÷1, preferably 150÷1, in such a way, that after initial cooling in a bath containing a supersaturated aqueous solution of the active admixture to a temperature ±30°C from the plastic transition temperature, preferably below the plastic transition temperature, it is stretched on calenders (by known methods of forming fibers or foils) to obtain an elongation of 5-20 times, preferably 10 times, which results in the formation of micropores in which the active admixture immobilizes, whereby in the variant with an extruded string, the elongation process is carried out linearly - maintaining the string form, or in two directions - forming a flat foil from the string. The second and final step of membrane fabrication is then performed, which is carried out in three ways depending on the form of the material obtained in step one, that is, either:
- according to variant a), wherein the material obtained in the first step in the form of a string is brought to a temperature within ±30°C from the plastic transition temperature, preferably exactly to the plastic transition temperature, after which it is stretched - by known methods - on calenders, preferably in two directions, so as to form a membrane in the form of a flat foil with a thickness between 0.2 and 200pm, preferably 30pm, or
- according to variant b), wherein the tubular material obtained in the first step is brought to a temperature within ±30°C from the plastic transition temperature, preferably exactly to the plastic transition temperature, and is then stretched - by known methods - on calenders, preferably in two directions, so as to obtain a membrane in the form of a tube with an outer diameter between 30 and 600pm, preferably 100pm, or
- according to variant c), wherein the material obtained in the first step in the form of a foil is brought to a temperature within ±30°C from the plastic transition temperature, preferably exactly to the plastic transition temperature, after which it is stretched - by known methods - on calenders, preferably in two directions, so as to obtain a membrane in the form of a flat foil with a thickness between 0.2 and 200 p , preferably 30pm.
In all variants a) and b) and c) of both the first and second variation of the method according to the invention, a porous membrane is formed, since during the stretching process pores with a size of 1 nm to 150 pm are produced, the membrane contains pores of which 40 to 60% are open pores (not filled) and the remaining pores are closed pores, i.e. they are filled with the active admixture.
As the membrane is used, the active admixture is gradually released and thus consumed, and the total amount of active admixture decreases and the number of open pores increases, resulting in a larger gas exchange surface area, i.e., better oxygenation. New pores are also formed that take over the gas exchange function from open pores that may have been blocked by progressively forming thrombi or biofilm formation on the membrane surface.
Flat membranes (foils) obtained in variants a) and c) are used after cutting from them the required shape for specific applications.
On the other hand, using the method according to variant b) hollow fiber tubes are obtained, which due to the porous structure of the wall can serve as cylindrical gas exchange membranes. Preferably, the tubes obtained in variant b) are cut into pieces of an appropriate length and then knitted on textile machines to form a membrane, most preferably with a distance of about 35 pm between the individual hollow fiber tubes in the knitted fabric and in this form they can preferably be used as membranes for oxygenating blood in oxygenators.
Preferably, the first step of the method according to the invention in the second variation is carried out in a glass or ceramic or stainless steel reactor.
Preferably, the first step of the method according to the invention in the second variation is carried out in a reactor in the form of a round-bottomed three-necked flask, due to its good functional properties.
Preferably, in the method according to the invention in the second variation, argon or nitrogen or xenon is used as the inert gas.
Preferably, in the method according to the invention in the second variation, anhydrous ethanol is used as the polar solvent.
Preferably, in the method according to the first or second variation, the base material is added in the form of a crushed material or aggregate or most preferably granulate.
Preferably, in the method according to the first or second variation, during the calendering step during the immobilization of the active admixture, a cyclic decrease and increase of the stress is applied, which increases the efficiency of the immobilization of the active admixture in the pores of the material.
According to the invention, a membrane is obtained having pores oriented in the direction or directions of stretching. Their characteristic feature is the absence of sharp edges and cracks around the pores. Such membrane materials, characterized by pores with irregular morphology prevent low molecular weight materials, including organic ones, from depositing in the vicinity of possible pore fractures. The membrane, thanks to its smooth surfaces and pore orientation along the flow path, reduces the risk of thrombosis due to the absence of steric obstacles that could be centers of thrombosis (no thrombi formation on the surface of the material occurs). These types of membranes are relatively fragile, with little resistance to external forces. Thus, in medical applications, for example in blood oxygenation systems, such membranes can be used in their manufactured form due to the absence of external forces that can break the continuity of the material. However, in applications where the membrane film membrane is exposed to external forces, especially outdoor membranes (such as membranes for construction of tents), it is recommended that the membrane be stabilized with a natural loose knit to improve its strength, which will improve the mechanical performance of the membrane without changing its high selectivity.
The membranes obtained by the methods according to the invention are characterized by full controllability of the size of the pores formed as well as their arrangement along the axis of flow of gases and body fluids, which results in higher gas exchange efficiency. The analyses show that such membranes have better selectivity performance than membranes with rough edges at the pore boundaries. The solution according to the invention makes it possible to obtain membranes with a very wide range of pore sizes from nano/micro scale (application especially for oxygenation, gas exchange) to macro pore size of even tenths of a millimeter (application as waterproof, breathable materials).
The membrane is characterized by low flow resistance, i.e., it enables to maintain proper, i.e., unobstructed flow despite low pressure - which is a result of the directional pore arrangement created by the directional stretching process on the calenders and the orientation of the macromolecules that results from such stretching. In the absence of this orientation of the pore system, turbulence would occur to interfere with the flow, resulting in an increase in flow resistance and consequently an increase in pressure.
In the membrane according to the invention, a decrease in gas flow pressure on one side of the membrane results in an increase in oxygen saturation while maintaining flow parameters, which results in better oxygenation of blood flowing on the other side of the membrane due to the maintenance of laminar flow continuity.
An additional advantage is that the material used does not release chemicals toxic to cells and does not itself cause pathogenic reactions on cells.
A membrane constructed from the materials described above protects against biofilm formation (no bacterial plaque forms on it), due to the internal structure of the material, i.e. the arrangement of macromolecules and pores in the material, which is not a protagonist of bacterial plaque development and adhesion.
The chemical structure of macromolecules of materials for construction of membranes obtained by the method according to the invention affects their good pore-forming, anti inflammatory and anticoagulant properties and at the same time ensures their biocompatibility and bioinertness (full neutrality). When these materials are used to manufacture membranes for oxygenators, the risk of inducing inflammation in cells is reduced, and thus the process of coagulation on the membrane slows down. The method according to the invention makes it possible to obtain membranes made of materials with a pore size in the nano range so that a single molecule of oxygen and carbon dioxide is able to penetrate the pores, and at the same time so that the pores are smaller than the macromolecular packets of which body fluids are composed, which in effect makes it possible to effectively oxygenate the blood without the risk of blood molecules penetrating the pores. Additionally, the method of pore formation in the process of directional stretching causes the pores to be oriented along the longitudinal axis of the hollow fiber tube or foil which ensures laminarity of the flow (the flow is not turbulent).
Studies on the ability of releasing the active admixture in the form of albumin or argatroban or bivalirudin or fondaparinux or heparin from the membrane obtained by the method according to the invention were carried out in a known flow-through vessel using a constant volume of polar solvent in the form of 18.2 MW ultrapure water. The membrane was immersed in the solvent for 30 minutes. The solvent was then extracted and injected into the flow-through vessel and changes in the frequency of disc vibrations in the form of a quartz resonator with an applied electrode were observed, in accordance with Sauerbrey's relation, i.e. the relation linking the change in vibration to the change in mass. The disc was positioned so that possible sedimentation of the analyte from the solvent would not falsify the result by gravitational settling on the disc. Positioning of the disc ensured that only the mass of the absorbed analyte was measured. Based on the observed changes in the frequency of disc vibrations (decrease of vibrations), the presence of an active admixture in the solvent was found to be deposited on the electrode. This indicates that when the membrane was immersed in the solvent, the active admixture was released from the membrane into the solvent. The experiment was repeated ten times on the same sample and the measurement results were similar each time
(within the measurement error). The constancy of the changes over time indicates a controlled process of releasing the active admixture from the membrane.
The use of an immobilized active admixture allows its concentration on the part contact surface to remain constant throughout the application of the materials (planned product life). The possibility of excessive leaching of the active admixture is minimized, and because of the diffusion-controlled release of the active admixture, its contact concentration on the product surface is constant.
Introduction of the active admixture into the material of the membrane according to the invention also gives the material the desired anticoagulant and anti-inflammatory properties. The active admixture as noted above has potent blood anticoagulant activity and due to its effect on lipids through lipase activation it is also used as an anticoagulant agent used for anticoagulant coatings. The active admixture is embedded both in the pores of the material and in microcracks formed as equilibrium defects during the material formation step. This significantly improves the surface continuity of the material structure and thus prevents organic material from depositing in pores and microcracks and significantly reduces coagulation.
Introduction of 4-(diphenylamino)benzaldehyde and 1,3-indandione admixtures in the invention according to the second variation results in a reduction of the internal stresses of the material which results in a better orientation of the macromolecules during processing and pore formation, which is ultimately observed as a smooth outer structure so that there are no mechanical steric centers for thrombus formation due to the uniformity of the material as well as the absence of sharp edges around the pores and cracks.
A method for preparing a membrane made of an organic material with pore-forming, anti-inflammatory and anticoagulant properties according to the invention will be further explained by means of the following examples.
Example 1
PTFE granules are introduced into a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for PTFE and hollow fiber tubes with an outer diameter of 2 mm are extruded on a cross head, and in the next step the process of immobilization of albumin into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PTFE-albumin ratio of 1200÷1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of albumin to a temperature of 180°C, i.e. below the plastic transition temperature, it is stretched
on calenders, by cyclically decreasing and increasing the tension so as to obtain an elongation of 10 times, which results in the formation of micropores in which albumin is immobilized. Then, the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a hollow fiber tube is brought to a temperature of 175°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a hollow fiber tube with an outer diameter of 600pm.
As a result, a membrane with albumin introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of albumin, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange. The hollow fiber tubes thus obtained can be spun on textile machines into knitted fabrics so that in the knitted fabric the distance between individual hollow fiber tubes is 35 pm and in this form they can be used as membranes for blood oxygenation in oxygenators.
Example 2
PTFE granules are introduced into a twin-screw ten-zone extruder with counter-rotating screws arrangement and geometry specified for PTFE and a foil of thickness 3 mm is extruded on a flat head and in the next step the process of immobilization of albumin into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PTFE/albumin ratio of 80÷1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of albumin to 300°C, i.e. below the plastic transition temperature, it is stretched on calenders, by cyclically decreasing and increasing the tension, so as to obtain an elongation of 5 times, which results in the formation of micropores in which albumin is immobilized.
Then, the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a flat foil is brought to a temperature of 295°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a 200 pm thick flat foil.
As a result, a membrane with albumin introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of albumin, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
These membranes can be used as gas-exchanging surfaces in flat membrane oxygenators or as osmotic membranes.
Example 3
PVDF aggregate is introduced into a twin-screw ten-zone extruder with counter-rotating screws arrangement and geometry specified for PVDF and a string with an outer diameter of 10 mm is extruded on a linear head and in the next step the process of immobilization of argatroban into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PVDF/argatroban ratio of 150÷1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of argatroban to 185°C, i.e. below the plastic transition temperature, it is stretched on calenders in two directions to form a flat foil, by cyclically decreasing and increasing the tension so as to obtain an elongation of 20 times, which results in the formation of micropores in which argatroban is immobilized.
Then, the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a foil is brought to a temperature of 180°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a 0,2pm thick foil.
As a result, a membrane with argatroban introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of argatroban, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
These membranes can be used as gas-exchanging surfaces in flat membrane oxygenators or as osmotic membranes.
Example 4
Milled FEP is introduced into a twin-screw ten-zone extruder with counter-rotating screws arrangement and geometry specified for FEP and hollow fiber tubes with an outer diameter of 10 mm are extruded on a cross head and in the next step the process of immobilization of argatroban into the steric structure of the material obtained in such a way that its content in the material in the FEP/argatroban ratio of 150÷1 is carried out in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of argatroban to a temperature of 245°C, i.e. below the plastic transition temperature, it is stretched on calenders by cyclically decreasing and increasing the tension so as to obtain an elongation of 10 times, which results in the formation of micropores in which argatroban is immobilized.
Then, the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a hollow fiber tube is brought to a temperature
of 240°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a hollow fiber tube with an outer diameter of 30mih.
As a result, a membrane with argatroban introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of argatroban, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange. The hollow fiber tubes thus obtained can be spun on textile machines into knitted fabrics so that in the knitted fabric the distance between individual hollow fiber tubes is 35 pm and in this form they can be used as membranes for blood oxygenation in oxygenators.
These membranes can be used as gas-exchanging surfaces in flat membrane oxygenators or as osmotic membranes.
Example 5
PVDF granulate is introduced into a twin-screw ten-zone extruder with counter-rotating screws arrangement and geometry specified for PVDF and a string with an outer diameter of 2 mm is extruded on a linear head and in the next step the process of immobilization of bivalirudin into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material with the PVDF/bivalirudin ratio of 150÷1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of bivalirudin to 185°C, i.e. below the plastic transition temperature, it is linearly stretched on calenders, so as to obtain an elongation of 20 times, which results in the formation of micropores in which bivalirudin is immobilized.
Then, the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a string is brought to a temperature of 180°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of 0.2pm thick foil.
As a result, a membrane with bivalirudin introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of bivalirudin, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
These membranes can be used as gas-exchanging surfaces in flat membrane oxygenators or as osmotic membranes.
The method according to the invention makes it possible to obtain membranes made of materials with anti-inflammatory and anticoagulant properties, especially for the construction
of medical equipment, in particular for components which are in direct contact with blood. Such membranes may, among other things, be used in oxygenators for blood oxygenation and as other gas- selective membranes.
Example 6
PTFE granules are introduced into a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for PTFE and hollow fiber tubes with an outer diameter of 2 mm are extruded on a cross head and in the next step the process of immobilization of fondaparinux into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PTFE/fondaparinux ratio of 1200÷1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of fondaparinux to a temperature of 180°C, i.e. below the plastic transition temperature, it is stretched on calenders, by cyclically decreasing and increasing the tension so as to obtain an elongation of 10 times, which results in the formation of micropores in which fondaparinux is immobilized.
Then, the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a hollow fiber tube is brought to a temperature of 175°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a hollow fiber tube with an outer diameter of 600p
As a result, a membrane with fondaparinux introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of fondaparinux, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange. The tubes thus obtained can be spun on textile machines into knitted fabrics so that in the knitted fabric the distance between individual hollow fiber tubes is 35 pm and in this form they can be used as membranes for blood oxygenation in oxygenators.
Example 7
PTFE granules are introduced into a twin-screw ten-zone extruder with counter-rotating screws arrangement and geometry specified for PTFE and a foil of thickness 3 mm is extruded on a flat head and in the next step the process of immobilization of heparin into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PTFE/heparin ratio of 80÷1, in such a way in that after initial cooling in a bath containing a supersaturated aqueous solution of heparin to 300°C, i.e. below the plastic transition temperature, it is stretched on calenders, by cyclically decreasing and increasing the tension, so
as to obtain an elongation of 5 times, which results in the formation of micropores in which heparin is immobilized.
Then, the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a flat foil is brought to a temperature of 295°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a 200 pm thick flat foil.
As a result, a membrane with heparin introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of heparin, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
These membranes can be used as gas-exchanging surfaces in flat membrane oxygenators or as osmotic membranes.
Example 8
In the first step, the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and sulfuric acid (VI) in proportions of 5÷0.002 is introduced into a dried round bottom three-neck glass flask in an argon atmosphere and 0.3 g of 4- (diphenylamino)benzaldehyde and 0.06 g of 1,3-indandione are added. The mixture is homogenized by stirring for 5 minutes and purged with argon for 30 minutes. It is then heated up to boiling under a reflux condenser in an argon atmosphere and stirred intensely at 400 rpm for 24 hours. After obtaining a homogeneous mixture, the solution is cooled down to 30°C and subjected to column chromatography in a S1O2 bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 1 times the volume of the reaction mixture, and of methylene chloride equal to 0.5 times the volume of the reaction mixture. The product is then vacuum-dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform. The product after recrystallization from chloroform (recry stallizate) is placed in a homogenizer and 300 g of polycarbonate (PC) granulate are added. The solution is mixed until a homogeneous mixture is obtained and dried for 24 hours at 90°C. Then - using a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for PC - hollow fiber tubes with an outer diameter of 2 mm are extruded on a cross head, and in the next step the process of immobilization of albumin into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PC/albumin ratio of 150÷1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of albumin to a temperature of
180°C, i.e. below the plastic transition temperature, it is stretched on calenders, by cyclically decreasing and increasing the tension so as to obtain an elongation of 8 times, which results in the formation of micropores in which albumin is immobilized.
Then, the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a hollow fiber tube is brought to a temperature of 175°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a flat hollow fiber tube with an outer diameter of 30pm
As a result, a membrane with albumin introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of albumin, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange. The tubes thus obtained can be spun on textile machines into knitted fabrics so that in the knitted fabric the distance between individual hollow fiber tubes is 35 pm and in this form they can be used as membranes for blood oxygenation in oxygenators.
Example 9
In the first step, the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and hydrochloric acid in proportions of 5 ÷ 0.002 is introduced into a dried stainless steel reactor in a xenon atmosphere and 0.5 g of 4- (diphenylamino)benzaldehyde and 0.02 g of 1,3-indandione are added. The mixture is homogenized by stirring for 1 minute and purged with xenon for 10 minutes. It is then heated up to boiling under a reflux condenser in a xenon atmosphere and stirred intensely at 350 rpm for 20 hours. After obtaining a homogeneous mixture, the solution is cooled down to 35°C and subjected to column chromatography in a SiC bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 2 times the volume of the reaction mixture, and of methylene chloride equal to 1 times the volume of the reaction mixture. The product is then vacuum-dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform. The product after recrystallization from chloroform (recry stallizate) is placed in a homogenizer and 25g polyurethane (PU) aggregate are added. The solution is mixed until a homogeneous mixture is obtained and dried for 20 hours at 105°C. Then - using a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for polyurethane - a hollow fiber tube with an outer diameter of 8 mm is extruded from the material on a cross head, and in the next step the process of immobilization of albumin into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PU/albumin ratio of 80÷1, in such a way that after
initial cooling in a bath containing a supersaturated aqueous solution of albumin to a temperature of 180°C, i.e. below the plastic transition temperature, it is stretched on calenders, by cyclically decreasing and increasing the tension so as to obtain an elongation of 5 times, which results in the formation of micropores in which albumin is immobilized.
Then, the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a hollow fiber tube is brought to a temperature of 175°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a hollow fiber tube with an outer diameter of 600pm.
As a result, a membrane with albumin introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of albumin, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
The tubes thus obtained can be spun on textile machines into knitted fabrics so that in the knitted fabric the distance between individual hollow fiber tubes is 30 pm and in this form they can be used as membranes for blood oxygenation in oxygenators.
Example 10
In the first step, the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and acetic acid in proportions of 5÷0.002 is introduced into a dried round bottom three-neck glass flask in an argon atmosphere and 0.7 g of 4- (diphenylamino)benzaldehyde and 0.08 g of 1,3-indandione are added. The mixture is homogenized by stirring for 3 minutes and purged with argon for 45 minutes. It is then heated up to boiling under a reflux condenser in an argon atmosphere and stirred intensely at 450 rpm for 24 hours. After obtaining a homogeneous mixture, the solution is cooled down to 30°C and subjected to column chromatography in a S1O2 bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 1 times the volume of the reaction mixture, and of methylene chloride equal to 0.5 times the volume of the reaction mixture. The product is then vacuum-dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform. The product after recrystallization from chloroform (recry stallizate) is placed in a homogenizer and 350 g of milled polypropylene (PP) are added. The solution is mixed until a homogeneous mixture is obtained and dried for 24 hours at 110°C. Then - using a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for polypropylene - a hollow fiber tube with an outer diameter of 10 mm is extruded from the material on a cross head, and in the next step the process of immobilization
of argatroban into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PP/argatroban ratio of 80÷1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of argatroban to a temperature of 150°C, i.e. below the plastic transition temperature, it is stretched on calenders, by cyclically decreasing and increasing the tension so as to obtain an elongation of 20 times, which results in the formation of micropores in which argatroban is immobilized.
Then, the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a hollow fiber tube is brought to a temperature of 145°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a hollow fiber tube with an outer diameter of 100 pm.
As a result, a membrane with argatroban introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of argatroban, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange. The tubes thus obtained can be spun on textile machines into knitted fabrics so that in the knitted fabric the distance between individual hollow fiber tubes is 35 pm and in this form they can be used as membranes for blood oxygenation in oxygenators.
Example 11
In the first step, the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and acetic acid in proportions of 5 ÷ 0.002 is introduced into a dried ceramic reactor in an argon atmosphere and 0.7 g of 4-(diphenylamino)benzaldehyde and 0.08 g of 1,3-indandione are added. The mixture is homogenized by stirring for 2 minutes and purged with argon for 45 minutes. It is then heated up to boiling under a reflux condenser in an argon atmosphere and stirred intensely at 450 rpm for 24 hours. After obtaining a homogeneous mixture, the solution is cooled down to 30°C and subjected to column chromatography in a S1O2 bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 1 times the volume of the reaction mixture, and of methylene chloride equal to 0.5 times the volume of the reaction mixture. The product is then vacuum-dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform. The product after recrystallization from chloroform (recrystallizate) is placed in a homogenizer and 350 g of poly(ethylene terephthalate) (PET) granulate are added. The solution is mixed until a homogeneous mixture is obtained and dried for 24 hours at 110°C. Then - using a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for PET - a 1 mm thick foil is extruded from the material on a flat head, and in the
next step the process of immobilization of argatroban into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PET/argatroban ratio of 700÷1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of argatroban to a temperature of 230°C, i.e. below the plastic transition temperature, it is stretched on calenders, by cyclically decreasing and increasing the tension so as to obtain an elongation of 15 times, which results in the formation of micropores in which argatroban is immobilized. Then, the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a foil is brought to a temperature of 225°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a 1 Opm thick flat foil.
As a result, a membrane with argatroban introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of argatroban, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
Example 12
In the first step, the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and sulfuric acid (VI) in proportions of 6 ÷ 0.002 is introduced into a dried round bottom three-neck glass flask in a nitrogen atmosphere and 0.7 g of 4-(diphenylamino)benzaldehyde and 0.08 g of 1,3-indandione are added. The mixture is homogenized by stirring for 1 minute and purged with nitrogen for 35 minutes. It is then heated up to boiling under a reflux condenser in a nitrogen atmosphere and stirred intensely at 600 rpm for 30 hours. After obtaining a homogeneous mixture, the solution is cooled down to 25°C and subjected to column chromatography in a S1O2 bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 0.5 times the volume of the reaction mixture, and of methylene chloride equal to 0.5 times the volume of the reaction mixture. The product is then vacuum-dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform. The product after recrystallization from chloroform (recry stallizate) is placed in a homogenizer and 71 g of poly(tetrafluoroethylene) (PTFE) granulate are added. The solution is mixed until a homogeneous mixture is obtained and dried for 24 hours at 100°C. Then - using a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for poly(tetrafluoroethylene) - a 0.5 mm thick foil is extruded from the material on a flat head, and in the next step the process of immobilization of argatroban into the steric structure of the material thus obtained is carried out in such a way
as to ensure its content in the material in the PTFE/argatroban ratio of 450÷1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of argatroban to a temperature of 300°C, i.e. below the plastic transition temperature, it is stretched on calenders, by cyclically decreasing and increasing the tension so as to obtain an elongation of 12 times, which results in the formation of micropores in which argatroban is immobilized. Then, the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a foil is brought to a temperature of 295°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a 5 pm thick flat foil.
As a result, a membrane with argatroban introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of argatroban, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
Example 13
In the first step, the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and hydrochloric acid in proportions of 3 ÷ 0.002 is introduced into a dried round bottom three-neck glass flask in a nitrogen atmosphere and 0.7 g of 4-(diphenylamino)benzaldehyde and 0.08 g of 1,3-indandione are added. The mixture is homogenized by stirring for 2 minutes and purged with nitrogen for 60 minutes. It is then heated up to boiling under a reflux condenser in a nitrogen atmosphere and stirred intensely at 500 rpm for 24 hours. After obtaining a homogeneous mixture, the solution is cooled down to 25°C and subjected to column chromatography in a S1O2 bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 2 times the volume of the reaction mixture, and of methylene chloride equal to 2 times the volume of the reaction mixture. The product is then vacuum-dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform. The product after recrystallization from chloroform (recry stallizate) is placed in a homogenizer and 140 g of poly oxy methylene (POM) granulate are added. The solution is mixed until a homogeneous mixture is obtained and dried for 20 hours at 110°C. Then - using a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for POM - an 8 mm thick string is extruded from the material on a linear head, and in the next step the process of immobilization of bivalirudin into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the POM/bivalirudin ratio of 100÷1, in such a way that after initial
cooling in a bath containing a supersaturated aqueous solution of bivalirudin to a temperature of 180°C, i.e. below the plastic transition temperature, it is linearly stretched on calenders, by cyclically decreasing and increasing the tension so as to obtain an elongation of 14 times, which results in the formation of micropores in which bivalirudin is immobilized. Then, the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a string is brought to a temperature of 175°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a 35 pm thick flat foil.
As a result, a membrane with bivalirudin introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of bivalirudin, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
Example 14
In the first step, the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and hydrochloric acid in proportions of 3 ÷ 0.002 is introduced into a dried round bottom three-neck glass flask in a nitrogen atmosphere and 0.7 g of 4-(diphenylamino)benzaldehyde and 0.08 g of 1,3-indandione are added. The mixture is homogenized by stirring for 2 minutes and purged with nitrogen for 60 minutes. It is then heated up to boiling under a reflux condenser in nitrogen atmosphere and stirred intensely at 900 rpm for 20 hours. After obtaining a homogeneous mixture, the solution is cooled down to 25°C and subjected to column chromatography in a S1O2 bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 2 times the volume of the reaction mixture, and of methylene chloride equal to 2 times the volume of the reaction mixture. The product is then vacuum-dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform. The product after recrystallization from chloroform (recry stallizate) is placed in a homogenizer and 310 g of polysulfone (PSU) granulate are added. The solution is mixed until a homogeneous mixture is obtained and dried for 30 hours at 90°C. Then - using a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for polysulfone - a 3 mm thick foil is extruded from the material on a flat head, and in the next step the process of immobilization of bivalirudin into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PSU/bivalirudin ratio of 1200÷1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of bivalirudin to a temperature of 190°C, i.e.
below the plastic transition temperature, it is stretched on calenders, by cyclically decreasing and increasing the tension so as to obtain an elongation of 8 times, which results in the formation of micropores in which bivalimdin is immobilized. Then, the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a foil is brought to a temperature of 185°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a 200pm thick flat foil.
As a result, a membrane with bivalimdin introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of bivalimdin, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
Example 15
In the first step, the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and sulfuric acid (VI) in proportions of 5 ÷ 0.002 is introduced into a dried round bottom three-neck glass flask in an argon atmosphere and 0.3 g of 4-(diphenylamino)benzaldehyde and 0.06 g of 1,3-indandione are added. The mixture is homogenized by stirring for 4 minutes and purged with argon for 30 minutes. It is then heated up to boiling under a reflux condenser in an argon atmosphere and stirred intensely at 500 rpm for 24 hours. After obtaining a homogeneous mixture, the solution is cooled down to 30°C and subjected to column chromatography in a S1O2 bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 0.5 times the volume of the reaction mixture, and of methylene chloride equal to 0.5 times the volume of the reaction mixture. The product is then vacuum-dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform. The product after recrystallization from chloroform (recry stallizate) is placed in a homogenizer and 150 g of polyvinylidene fluoride (PVDF) granulate are added. The solution is mixed until a homogeneous mixture is obtained and dried for 24 hours at 90°C. Then - using a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for PVDF - a 2.5 mm thick foil is extruded from the material on a flat head, and in the next step the process of immobilization of bivalirudin into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PVDF/bivalirudin ratio of 150÷1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of bivalirudin to a temperature of 185°C, i.e. below the plastic transition temperature, it is stretched on calenders, by cyclically decreasing and increasing the tension so as to obtain an elongation of 10 times, which results
in the formation of micropores in which bivalirudin is immobilized. Then, the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a foil is brought to a temperature of 180°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a 1 p thick flat foil.
As a result, a membrane with bivalirudin introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of bivalirudin, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
Example 16
In the first step, the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and hydrochloric acid in proportions of 2÷0.002 is introduced into a dried round-bottomed triple-necked glass flask in a nitrogen atmosphere and 0.5 g of 4- (diphenylamino)benzaldehyde and 0.02 g of 1,3-indandione are added. The mixture is homogenized by stirring for 1 minute and purged with nitrogen for 10 minutes. It is then heated up to boiling under a reflux condenser in a nitrogen atmosphere and stirred intensely at 400 rpm for 30 hours. After obtaining a homogeneous mixture, the solution is cooled down to 25°C and subjected to column chromatography in a S1O2 bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 2 times the volume of the reaction mixture, and of methylene chloride equal to 2 times the volume of the reaction mixture. The product is then vacuum-dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform. The product after recrystallization from chloroform (recry stallizate) is placed in a homogenizer and 50 g of a copolymer of tetrafluoroethylene and hexafluoropropylene (FEP) granulate are added. The solution is mixed until a homogeneous mixture is obtained and dried for 30 hours at 95°C. Then - using a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for FEP - a string with an outer diameter of 2 mm is extruded from the material on a linear head, and in the next step the process of immobilization of fondaparinux into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the FEP/fondaparinux ratio of 120÷1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of fondaparinux to a temperature of 245°C, i.e. below the plastic transition temperature, it is stretched on calenders, by cyclically decreasing and increasing the tension so as to obtain an elongation of 8 times, which results in the formation of micropores in which fondaparinux is immobilized. Then, the second, final step of membrane production is carried out in such a
way that the material obtained in the first step in the form of a foil is brought to a temperature of 240°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a 30pm thick flat foil.
As a result, a membrane with fondaparinux introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of fondaparinux, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
Example 17
In the first step, the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and sulfuric acid (VI) in proportions of 5 ÷ 0.002 is introduced into a dried round bottom three-neck glass flask in an argon atmosphere and 0.3 g of 4-(diphenylamino)benzaldehyde and 0.06 g of 1,3-indandione are added. The mixture is homogenized by stirring for 5 minutes and purged with argon for 30 minutes. It is then heated up to boiling under a reflux condenser in an argon atmosphere and stirred intensely at 400 rpm for 24 hours. After obtaining a homogeneous mixture, the solution is cooled down to 30°C and subjected to column chromatography in a SiC bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 1 times the volume of the reaction mixture, and of methylene chloride equal to 0.5 times the volume of the reaction mixture. The product is then vacuum-dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform. The product after recrystallization from chloroform (recry stallizate) is placed in a homogenizer and 300 g of polycarbonate (PC) granulate are added. The solution is mixed until a homogeneous mixture is obtained and dried for 24 hours at 90°C. Then - using a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for PC - hollow fiber tubes with an outer diameter of 2 mm are extruded from the material on a cross head, and in the next step the process of immobilization of fondaparinux into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PC/fondaparinux ratio of 150÷1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of fondaparinux to a temperature of 180°C, i.e. below the plastic transition temperature, it is stretched on calenders, by cyclically decreasing and increasing the tension so as to obtain an elongation of 8 times, which results in the formation of micropores in which fondaparinux is immobilized.
Then, the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a hollow fiber tube is brought to a temperature of 175°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a flat hollow fiber tube with an outer diameter of 30pm.
As a result, a membrane with fondaparinux introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of fondaparinux, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange. The tubes thus obtained can be spun on textile machines into knitted fabrics so that in the knitted fabric the distance between individual hollow fiber tubes is 35 pm and in this form they can be used as membranes for blood oxygenation in oxygenators.
Example 18
In the first step, the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and hydrochloric acid in proportions of 5 ÷ 0.002 is introduced into a dried stainless steel reactor in a xenon atmosphere and 0.5 g of 4- (diphenylamino)benzaldehyde and 0.02 g of 1,3-indandione are added. The mixture is homogenized by stirring for 1 minute and purged with xenon for 10 minutes. It is then heated up to boiling under a reflux condenser in a xenon atmosphere and stirred intensely at 350 rpm for 20 hours. After obtaining a homogeneous mixture, the solution is cooled down to 35°C and subjected to column chromatography in a SiC bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 2 times the volume of the reaction mixture, and of methylene chloride equal to 1 times the volume of the reaction mixture. The product is then vacuum-dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform. The product after recrystallization from chloroform (recry stallizate) is placed in a homogenizer and 25g polyurethane (PU) aggregate are added. The solution is mixed until a homogeneous mixture is obtained and dried for 20 hours at 105°C. Then - using a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for polyurethane - a hollow fiber tube with an outer diameter of 8 mm is extruded from the material on a cross head, and in the next step the process of immobilization of heparin into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PU/heparin ratio of 80÷1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of heparin to a temperature of 180°C, i.e. below the plastic transition temperature, it is stretched on calenders, by cyclically
decreasing and increasing the tension so as to obtain an elongation of 5 times, which results in the formation of micropores in which heparin is immobilized.
Then, the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a hollow fiber tube is brought to a temperature of 175°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a hollow fiber tube with an outer diameter of 600pm.
As a result, a membrane with heparin introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of heparin, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
The tubes thus obtained can be spun on textile machines into knitted fabrics so that in the knitted fabric the distance between individual hollow fiber tubes is 30 pm and in this form they can be used as membranes for blood oxygenation in oxygenators.
Example 19
In the first step, the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and acetic acid in proportions of 5 ÷ 0.002 is introduced into a dried round-bottomed triple-necked glass flask in an argon atmosphere and 0.7 g of 4- (diphenylamino)benzaldehyde and 0.08 g of 1,3-indandione are added. The mixture is homogenized by stirring for 3 minutes and purged with argon for 45 minutes. It is then heated up to boiling under a reflux condenser in an argon atmosphere and stirred intensely at 450 rpm for 24 hours. After obtaining a homogeneous mixture, the solution is cooled down to 30°C and subjected to column chromatography in a S1O2 bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 1 times the volume of the reaction mixture, and of methylene chloride equal to 0.5 times the volume of the reaction mixture. It is then vacuum-dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform. The product after recrystallization from chloroform (recry stallizate) is placed in a homogenizer and 350g of milled polypropylene (PP) are added. The solution is mixed until a homogeneous mixture is obtained and dried for 24 hours at 110°C. Then - using a twin-screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for polypropylene - a hollow fiber tube with an outer diameter of 10 mm is extruded from the material on a cross head, and in the next step the process of immobilization of heparin into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PP/heparin ratio of 80÷1, in such a way that after
initial cooling in a bath containing a supersaturated aqueous solution of heparin to a temperature of 150°C, i.e. below the plastic transition temperature, it is stretched on calenders, by cyclically decreasing and increasing the tension so as to obtain an elongation of 20 times, which results in the formation of micropores in which heparin is immobilized.
Then, the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a hollow fiber tube is brought to a temperature of 145°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a hollow fiber tube with an outer diameter of 100 pm.
As a result, a membrane with heparin introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of heparin, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange. The tubes thus obtained can be spun on textile machines into knitted fabrics so that in the knitted fabric the distance between individual hollow fiber tubes is 35 pm and in this form they can be used as membranes for blood oxygenation in oxygenators.
Example 20
In the first step, the material for membrane construction is produced in such a way that 50 mL of a mixture of anhydrous ethanol and acetic acid in proportions of 5 ÷ 0.002 is introduced into a dried ceramic reactor in an argon atmosphere and 0.7 g of 4-(diphenylamino)benzaldehyde and 0.08 g of 1,3-indandione are added. The mixture is homogenized by stirring for 2 minutes and purged with argon for 45 minutes. It is then heated up to boiling under a reflux condenser in an argon atmosphere and stirred intensely at 450 rpm for 24 hours. After obtaining a homogeneous mixture, the solution is cooled down to 30°C and subjected to column chromatography in a S1O2 bed and in a mobile phase of the mixture of hexane and methylene chloride, with the amount of hexane equal to 1 times the volume of the reaction mixture, and of methylene chloride equal to 0.5 times the volume of the reaction mixture. It is then vacuum- dried for at least 24 hours to constant weight, after which it is recrystallized from chloroform. The product after recrystallization from chloroform (recrystallizate) is placed in a homogenizer and 350 g of poly(ethylene terephthalate) (PET) granulate are added. The solution is mixed until a homogeneous mixture is obtained and dried for 24 hours at 110°C. Then - using a twin- screw ten-zone extruder with a counter-rotating screws arrangement and geometry specified for PET - a 1 mm thick foil is extruded from the material on a flat head, and in the next step the process of immobilization of heparin into the steric structure of the material thus obtained is carried out in such a way as to ensure its content in the material in the PET/heparin ratio of
700÷1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of heparin to a temperature of 230°C, i.e. below the plastic transition temperature, it is stretched on calenders, by cyclically decreasing and increasing the tension so as to obtain an elongation of 15 times, which results in the formation of micropores in which heparin is immobilized. Then, the second, final step of membrane production is carried out in such a way that the material obtained in the first step in the form of a foil is brought to a temperature of 225°C, after which it is stretched on calenders, in two directions, so as to obtain a membrane in the form of a 1 Opm thick flat foil.
As a result, a membrane with heparin introduced into its pores is obtained, which can be used, for example, in blood oxygenation systems, because due to its structure and the possibility of controlled release of heparin, it prevents thrombus formation while maintaining very high osmotic gas-selective exchange.
The method according to the invention makes it possible to obtain membranes made of materials with pore-forming, anti-inflammatory and anticoagulant properties, especially intended for the construction of medical equipment, in particular for construction of components which are in direct contact with blood. Such membranes may, among other things, be used in oxygenators for blood oxygenation and as other gas-selective membranes.
Claims
1. A membrane characterized in that it is either a flat foil of thickness from 0.2 to 200mih, preferably 30pm, or a hollow fiber tube of outer diameter from 30 to 600pm, preferably lOOpm, and it is made of an organic material with pore-forming, anti-inflammatory and anticoagulant properties comprising:
- base in the form of a fluoropolymer, preferably poly(tetrafluoroethylene) (PTFE, Teflon) or polyvinylidene fluoride (PVDF) or a copolymer of tetrafluoroethylene and hexafluoropropylene (FEP), and
- active admixture in the form of albumin or argatroban or bivalirudin or fondaparinux or heparin, embedded in the microstructure of the base material, in the base/active admixture ratio from 80÷1 to 1200÷1, preferably 150÷1.
2. A membrane characterized in that it is either a flat foil of thickness from 0.2 to 200pm, preferably 30pm, or a hollow fiber tube of outer diameter from 30 to 600pm, preferably 100pm, and is made of an organic material with pore-forming, anti-inflammatory and anticoagulant properties comprising:
- base in the form of polypropylene (PP) or polyurethane (PU) or polyethylene terephthalate (PET) or polycarbonate (PC) or polyoxymethylene (POM) or polysulfone (PSU) or silicone or fluoropolymer, preferably poly(tetrafluoroethylene) (PTFE) or polyvinylidene fluoride (PVDF) or a copolymer of tetrafluoroethylene and hexafluoropropylene (FEP),
- 4-(diphenylamino)benzaldehyde admixture in a base/admixture ratio from 50÷1 to 5000÷1, preferably 100÷1,
- admixture of 1,3-indandione in a base/admixture ratio from 50÷1 to 5000÷1, preferably 100÷1, and
- active admixture in the form of albumin or argatroban or bivalirudin or fondaparinux or heparin, embedded into the micro structure of the base material, in the base/active admixture ratio from 80÷1 to 1200÷1, preferably 150÷1.
3. A method for obtaining a membrane made of an organic material with pore-forming, anti inflammatory and anticoagulant properties, characterized in that the material in the form of a fluoropolymer, preferably poly(tetrafluoroethylene) (PTFE, Teflon) or polyvinylidene fluoride (PVDF) or a copolymer of tetrafluoroethylene and hexafluoropropylene (FEP) is extruded on a linear head in the form of a string, preferably with an outer diameter of 2 to 10 mm, or, on a cross head in the form of a hollow fiber tube, preferably with an outer diameter of 2 to 10 mm, or on a flat head in the form of a flat foil, preferably with a thickness of 0.1 to 3 mm, then the
process of immobilization of active admixture in the form of albumin or argatroban or bivalirudin or fondaparinux or heparin into the steric structure of the material thus obtained is carried out in a manner ensuring its content in the material in the base/active admixture ratio from 80÷1 to 1200÷1, preferably 150÷1, in such a way, that after initial cooling in a bath containing a supersaturated aqueous solution of the active admixture to a temperature within ±30°C from the plastic transition temperature, preferably below the plastic transition temperature, it is stretched on calenders, so as to obtain an elongation of 5 to 20 times, preferably 10 times, which results in the formation of micropores in which the active admixture is immobilized, whereby in a variant with an extruded string, the elongation process is carried out linearly - while maintaining the string form, or, in two directions - forming a flat foil from the string, then the second, final step of membrane production is carried out, which is performed in three ways depending on the form of the material obtained in the first step, namely either:
- according to variant a), wherein the material obtained in the first step in the form of a string is brought to a temperature within ±30°C from the plastic transition temperature, preferably exactly to the plastic transition temperature, after which it is stretched - by known methods - on calenders, preferably in two directions, so as to obtain a membrane in the form of a flat foil with a thickness between 0.2 and 200pm, preferably 30pm, or
- according to variant b), wherein the material in the form of a hollow fiber tube obtained in the first step is brought to a temperature within ±30°C from the plastic transition temperature, preferably exactly to the plastic transition temperature, and is then stretched - by known methods on calenders - preferably in two directions, to obtain a membrane in the form of a hollow fiber tube with an outer diameter between 30 and 600 pm, preferably 100 pm, or
- according to variant c), wherein the material obtained in the first step in the form of a foil is brought to a temperature within ±30°C from the plastic transition temperature, preferably exactly to the plastic transition temperature, after which it is stretched - by known methods - on calenders, preferably in two directions, so as to obtain a membrane in the form of a flat foil with a thickness between 0.2 and 200pm, preferably 30pm.
4. A method for obtaining a membrane from an organic material with pore-forming, anti inflammatory and anticoagulant properties, characterized in that in the first step a material for membrane construction is produced in such a way that a polar solvent and an acid selected from the following ones are introduced into a reactor made of a non-reactive material in an inert gas atmosphere: sulfuric acid VI, hydrochloric acid or acetic acid, in proportions from 2÷0.002 to 7÷0.002, preferably 5÷0.002, and then 4-(diphenylamino)benzaldehyde in the amount from 0.2 g to 0.7 g and 1,3-indandione in the amount from 0.01 g to 0.08 g is added per 50mL of a
mixture thus obtained and stirred to a homogeneous mixture for not less than 1 minute, after which the suspension is purged with the inert gas for at least 5 minutes, preferably not more than 60 minutes, heated up to boiling under a reflux condenser in an inert gas atmosphere and stirred intensely at 100-1000 rpm, preferably 350-450 rpm, for at least 18 hours, preferably not more than 30 hours, and after the mixing process the resulting mixture is cooled down to a temperature of 20 to 35°C and subjected to column chromatography in a S1O2 bed and in the mobile phase of a mixture of hexane and methylene chloride, with the amount of hexane from 0.5 to 2 times the volume of the reaction mixture, and methylene chloride from 0.5 to 2 times the volume of the reaction mixture, then vacuum-dried for at least 20 hours, preferably 24 hours to constant weight, followed by recrystallization from chloroform, after which the product after recrystallization from chloroform (recrystallizate) is placed in a homogenizer and the base is introduced as: polypropylene (PP) or polyurethane (PU) or polyethylene terephthalate (PET) or polycarbonate (PC) or polyoxymethylene (POM) or polysulfone (PSU) or silicone or fluoropolymer, preferably poly(tetrafluoroethylene) (PTFE) or polyvinylidene fluoride (PVDF) or a copolymer of tetrafluoroethylene and hexafluoropropylene (FEP), with the proportion of the base/recrystallizate from 50÷2 to 5000÷2, preferably 100÷2, and then mixed to a homogeneous mixture and dried for at least 20 hours at 80-110°C, after which the material is extruded on a linear head is extruded on a linear head in the form of a string, preferably with an outer diameter of 2 to 10 mm, or on a cross head in the form of a hollow fiber tube, preferably with an outer diameter of 2 to 10 mm, or on a flat head in the form of a foil preferably with a thickness of 0.1 to 3 mm, and in the next step the process of immobilization of the active admixture in the form of albumin or argatroban or bivalirudin or fondaparinux or heparin into the steric structure of the material thus obtained is carried out in a manner ensuring its content in the material with the ratio of base/active admixture from 80÷1 to 1200÷1, preferably 150÷1, in such a way that after initial cooling in a bath containing a supersaturated aqueous solution of the active admixture to a temperature within ±30°C from the plastic transition temperature, preferably below the plastic transition temperature, it is stretched on calenders, so as to obtain an elongation of 5-20 times, preferably 10 times, whereby in a variant with the extruded string, the elongation process is carried out linearly - maintaining the string form, or, in two directions
- forming a flat foil from the string, then the second, final step of membrane production is carried out, which is performed in three ways depending on the form of the material obtained in the first step, namely either:
- according to variant a), wherein the material obtained in the first step in the form of a string is brought to a temperature within ±30°C from the plastic transition temperature, preferably
exactly to the plastic transition temperature, after which it is stretched - by known methods - on calenders, preferably in two directions, so as to obtain a membrane in the form of a flat foil with a thickness between 0.2 and 200pm, preferably 30pm, or
- according to variant b), wherein the material in the form of a hollow fiber tube obtained in the first step is brought to a temperature within ±30°C from the plastic transition temperature, preferably exactly to the plastic transition temperature, and is then stretched - by known methods on calenders - preferably in two directions, to obtain a membrane in the form of a hollow fiber tube with an outer diameter between 30 and 600pm, preferably 100 p , or
- according to variant c), wherein the material obtained in the first step in the form of a foil is brought to a temperature within ±30°C from the plastic transition temperature, preferably exactly to the plastic transition temperature, after which it is stretched - by known methods - on calenders, preferably in two directions, so as to obtain a membrane in the form of a flat foil with a thickness between 0.2 and 200pm, preferably 30pm.
5. A method according to claim 3 or claim 4, characterized in that the hollow fiber tubes obtained in variant b) are cut into pieces of an appropriate length and then spun on textile machines to form a membrane, most preferably with a distance of approximately 35 pm between the individual hollow fiber tubes in the knitted fabric.
6. A method according to claim 4, characterized in that the first step of the method according to the invention is carried out in a glass or ceramic or stainless steel reactor.
7. A method according to claim 4, characterized in that the first step of the method according to the invention is carried out in a reactor having a form of a round -bottomed triple-neck glass flask.
8. A method according to claim 4, characterized in that argon or nitrogen or xenon is used as the inert gas.
9. A method according to claim 4, characterized in that anhydrous ethanol is used as the polar solvent.
10. A method according to claim 3 or claim 4, characterized in that the base material is added in the form of crushed fraction or aggregate or most preferably granulate.
11. A method according to claim 3 or claim 4, characterized in that in the calendering step during immobilization of the active agent in the form of albumin or argatroban or bivalirudin or fondaparinux or heparin, cyclic decreasing and increasing of tension is applied.
Applications Claiming Priority (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PLP.436120 | 2020-11-27 | ||
PL436119A PL240911B1 (en) | 2020-11-27 | 2020-11-27 | Membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof |
PLP.436121 | 2020-11-27 | ||
PLP.436122 | 2020-11-27 | ||
PL436122A PL240944B1 (en) | 2020-11-27 | 2020-11-27 | Membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof |
PLP.436116 | 2020-11-27 | ||
PLP.436118 | 2020-11-27 | ||
PL436117A PL240942B1 (en) | 2020-11-27 | 2020-11-27 | Membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof |
PLP.436119 | 2020-11-27 | ||
PL436116A PL240941B1 (en) | 2020-11-27 | 2020-11-27 | Membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof |
PL436120A PL240912B1 (en) | 2020-11-27 | 2020-11-27 | Membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof |
PL436118A PL240910B1 (en) | 2020-11-27 | 2020-11-27 | Membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof |
PL436121A PL240943B1 (en) | 2020-11-27 | 2020-11-27 | Membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof |
PLP.436115 | 2020-11-27 | ||
PLP.436113 | 2020-11-27 | ||
PL436114A PL240236B1 (en) | 2020-11-27 | 2020-11-27 | Membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof |
PLP.436117 | 2020-11-27 | ||
PLP.436114 | 2020-11-27 | ||
PL436113A PL240235B1 (en) | 2020-11-27 | 2020-11-27 | Membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof |
PL436115A PL240940B1 (en) | 2020-11-27 | 2020-11-27 | Membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022113019A1 true WO2022113019A1 (en) | 2022-06-02 |
Family
ID=81755675
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2021/061016 WO2022113019A1 (en) | 2020-11-27 | 2021-11-26 | A membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and the method of obtaining it |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022113019A1 (en) |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4229838A (en) * | 1977-07-01 | 1980-10-28 | Sumitomo Electric Industries, Ltd. | Vascular prosthesis having a composite structure |
KR20030076109A (en) * | 2002-03-22 | 2003-09-26 | 뉴하트 바이오(주) | Method for immobilization of antithrombotic proteins on polytetrafluoroethylene surface by plasma treatment |
JP2007229123A (en) * | 2006-02-28 | 2007-09-13 | National Cardiovascular Center | Stent |
US20080125857A1 (en) * | 2000-10-31 | 2008-05-29 | Advanced Cardiovascular Systems, Inc. | Hemocompatible polymers on hydrophobic porous polymers |
CN101745327A (en) * | 2009-12-29 | 2010-06-23 | 浙江大学 | Method for fixing biological molecules on polymer microporous membrane surface |
CN103055721A (en) * | 2013-01-30 | 2013-04-24 | 四川大学 | Preparation method for high-flux high-strength polytetrafluoroethylene hollow fibrous membrane |
CN103240006A (en) * | 2013-05-10 | 2013-08-14 | 天津大学 | Bovine serum albumin-polycarbonate composite membrane and preparation method thereof |
PL231827B1 (en) * | 2017-02-27 | 2019-04-30 | Univ Slaski | Organic bacteriostatic material |
-
2021
- 2021-11-26 WO PCT/IB2021/061016 patent/WO2022113019A1/en active Application Filing
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4229838A (en) * | 1977-07-01 | 1980-10-28 | Sumitomo Electric Industries, Ltd. | Vascular prosthesis having a composite structure |
US20080125857A1 (en) * | 2000-10-31 | 2008-05-29 | Advanced Cardiovascular Systems, Inc. | Hemocompatible polymers on hydrophobic porous polymers |
KR20030076109A (en) * | 2002-03-22 | 2003-09-26 | 뉴하트 바이오(주) | Method for immobilization of antithrombotic proteins on polytetrafluoroethylene surface by plasma treatment |
JP2007229123A (en) * | 2006-02-28 | 2007-09-13 | National Cardiovascular Center | Stent |
CN101745327A (en) * | 2009-12-29 | 2010-06-23 | 浙江大学 | Method for fixing biological molecules on polymer microporous membrane surface |
CN103055721A (en) * | 2013-01-30 | 2013-04-24 | 四川大学 | Preparation method for high-flux high-strength polytetrafluoroethylene hollow fibrous membrane |
CN103240006A (en) * | 2013-05-10 | 2013-08-14 | 天津大学 | Bovine serum albumin-polycarbonate composite membrane and preparation method thereof |
PL231827B1 (en) * | 2017-02-27 | 2019-04-30 | Univ Slaski | Organic bacteriostatic material |
Non-Patent Citations (5)
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gao et al. | Preparation and evaluation of heparin-immobilized poly (lactic acid)(PLA) membrane for hemodialysis | |
JP5011722B2 (en) | Method for producing medical separation membrane and method for producing medical separation membrane module using the medical separation membrane | |
EP0740680A1 (en) | Hydrocyclosiloxane membrane prepared by plasma polymerization process | |
US7151120B2 (en) | Degradable porous materials with high surface areas | |
Zhang et al. | Anticoagulant Hydrogel Tubes with Poly (ɛ‐Caprolactone) Sheaths for Small‐Diameter Vascular Grafts | |
He et al. | Membranes for extracorporeal membrane oxygenator (ECMO): History, preparation, modification and mass transfer | |
WO2022113019A1 (en) | A membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and the method of obtaining it | |
EP4251695A1 (en) | Organic material with pore-forming, anti-inflammatory and anticoagulant properties and the method of its preparation | |
PL240940B1 (en) | Membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof | |
PL240942B1 (en) | Membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof | |
PL240235B1 (en) | Membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof | |
PL240941B1 (en) | Membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof | |
PL240236B1 (en) | Membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof | |
PL240912B1 (en) | Membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof | |
PL240910B1 (en) | Membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof | |
PL240944B1 (en) | Membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof | |
PL240911B1 (en) | Membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof | |
PL240943B1 (en) | Membrane made of organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof | |
PL240233B1 (en) | Organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof | |
PL240234B1 (en) | Organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof | |
PL243070B1 (en) | Organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof | |
PL242956B1 (en) | Membrane made of organic material with pore-forming properties and method of preparation thereof | |
PL240231B1 (en) | Organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof | |
CN109966548A (en) | A kind of bilayer polymer Material cladding blood vessel | |
PL240232B1 (en) | Organic material with pore-forming, anti-inflammatory and anticoagulant properties and method of preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21897296 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21897296 Country of ref document: EP Kind code of ref document: A1 |